| FileMan FileNo | FileMan Filename | Package | 
|---|---|---|
| 165.5 | ONCOLOGY PRIMARY | Oncology | 
| Package | Total | FileMan Files | 
|---|---|---|
| Oncology | 1 | COMPUTED PRIMARY(#165.59)[.01] | 
| Field # | Name | Loc | Type | Details | 
|---|---|---|---|---|
| .01 | SITE/GP | 0;1 | POINTER TO SITE-GROUP FOR ONCOLOGY FILE (#164.2) | ************************REQUIRED FIELD************************ SITE-GROUP FOR ONCOLOGY(#164.2)
  | 
| .0101 | PRIMARY SITE/GP | COMPUTED | 
  | 
|
| .015 | SELECTED SITES | COMPUTED | 
  | 
|
| .017 | SYSTEMS | COMPUTED | 
  | 
|
| .02 | PATIENT NAME | 0;2 | POINTER TO ONCOLOGY PATIENT FILE (#160) | ************************REQUIRED FIELD************************ ONCOLOGY PATIENT(#160)
  | 
| .022 | ICDO-SITE | 0;22 | POINTER TO ICDO-SITES FILE (#164.08) | ************************REQUIRED FIELD************************ ICDO-SITES(#164.08)
  | 
| .023 | PRIMARY SITE CODE PREFIX | COMPUTED | 
  | 
|
| .025 | PATIENT ID | COMPUTED | 
  | 
|
| .03 | REPORTING FACILITY | 0;3 | POINTER TO FACILITY FILE (#160.19) | ************************REQUIRED FIELD************************ FACILITY(#160.19)
  | 
| .04 | CLASS OF CASE | 0;4 | POINTER TO CLASS OF CASE FILE (#165.3) | ************************REQUIRED FIELD************************ CLASS OF CASE(#165.3)
  | 
| .041 | CLASS NO. | COMPUTED | 
  | 
|
| .042 | CLASS CATEGORY | 0;20 | SET | ************************REQUIRED FIELD************************ 
 
  | 
| .043 | ANALYTIC PRIMARY REQ FOLLOWUP | COMPUTED | 
  | 
|
| .05 | ACCESSION NUMBER | 0;5 | FREE TEXT | ************************REQUIRED FIELD************************ 
  | 
| .06 | SEQUENCE NUMBER | 0;6 | FREE TEXT | 
  | 
| .061 | ACC/SEQ NUMBER | COMPUTED | 
  | 
|
| .07 | ACCESSION YEAR | 0;7 | FREE TEXT | ************************REQUIRED FIELD************************ 
  | 
| .08 | MEDICAL RECORD NUMBER | COMPUTED | 
  | 
|
| .09 | SOCIAL SECURITY NUMBER | COMPUTED | 
  | 
|
| .091 | STATUS | COMPUTED | 
  | 
|
| .093 | PLACE OF BIRTH (STATE) | COMPUTED | 
  | 
|
| .1 | SEX | COMPUTED | 
  | 
|
| .115 | STATE | COMPUTED | 
  | 
|
| .1157 | ST-COUNTY | COMPUTED | 
  | 
|
| .117 | COUNTY | COMPUTED | 
  | 
|
| .12 | RACE | COMPUTED | 
  | 
|
| .13 | RACE-SEX | COMPUTED | 
  | 
|
| .14 | SEX-RACE | COMPUTED | 
  | 
|
| 1 | DATE OF INPATIENT ADMISSION | 0;8 | DATE | 
  | 
| 1.1 | DATE OF INPATIENT DISCHARGE | 0;9 | DATE | 
  | 
| 1.2 | TYPE OF REPORTING SOURCE | 0;10 | POINTER TO TYPE OF REPORTING SOURCE FILE (#168) | TYPE OF REPORTING SOURCE(#168)
  | 
| 2 | PRIMARY SURGEON | 0;11 | POINTER TO ONCOLOGY CONTACT FILE (#165) | ONCOLOGY CONTACT(#165)
  | 
| 2.1 | FOLLOWING PHYSICIAN | 0;12 | POINTER TO ONCOLOGY CONTACT FILE (#165) | ONCOLOGY CONTACT(#165)
  | 
| 2.2 | MANAGING PHYSICIAN | 0;13 | POINTER TO ONCOLOGY CONTACT FILE (#165) | ONCOLOGY CONTACT(#165)
  | 
| 2.3 | PHYSICIAN #3 | 0;14 | POINTER TO ONCOLOGY CONTACT FILE (#165) | ONCOLOGY CONTACT(#165)
  | 
| 2.4 | PHYSICIAN #4 | 0;15 | POINTER TO ONCOLOGY CONTACT FILE (#165) | ONCOLOGY CONTACT(#165)
  | 
| 3 | DATE DX | 0;16 | DATE | ************************REQUIRED FIELD************************ 
  | 
| 3.1 | DIAGNOSIS EPISODE CARE | COMPUTED | 
  | 
|
| 3.5 | YEAR DX | COMPUTED DATE | 
  | 
|
| 4 | AGE AT DX | COMPUTED | 
  | 
|
| 4.1 | DX AGE-GP | COMPUTED | 
  | 
|
| 5 | DX FACILITY | 0;17 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
  | 
| 6 | FACILITY REFERRED FROM | 0;18 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
  | 
| 7 | FACILITY REFERRED TO | 0;19 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
  | 
| 8 | PATIENT ADDRESS AT DX | 1;1 | FREE TEXT | 
  | 
| 8.1 | CITY/TOWN AT DX | 1;12 | FREE TEXT | 
  | 
| 8.2 | PATIENT ADDRESS AT DX - SUPP | 1;13 | FREE TEXT | 
  | 
| 9 | POSTAL CODE AT DX | 1;2 | FREE TEXT | 
  | 
| 10 | COUNTY AT DX | 1;3 | FREE TEXT | 
  | 
| 11 | MARITAL STATUS AT DX | 1;5 | SET | 
 
  | 
| 12 | PALLIATIVE CARE | 3.1;26 | SET | 
 
  | 
| 13 | PALLIATIVE CARE @FAC | 3.1;27 | SET | 
 
  | 
| 14 | READMISSION W/I 30 DAYS/SURG | 3.1;28 | SET | 
 
  | 
| 15 | SYSTEMIC/SURGERY SEQUENCE | 3.1;39 | SET | 
 
  | 
| 16 | STATE AT DX | 1;4 | POINTER TO STATE FILE (#5) | STATE(#5)
  | 
| 17 | SUSPENSE DATE | 1;10 | DATE | 
  | 
| 18 | PRIMARY PAYER AT DX | 1;11 | POINTER TO PRIMARY PAYER AT DIAGNOSIS FILE (#160.3) | PRIMARY PAYER AT DIAGNOSIS(#160.3)
  | 
| 19 | STAGED BY (CLINICAL STAGE) | 3;32 | POINTER TO ONCOLOGY STAGED BY CODES FILE (#165.7) | ONCOLOGY STAGED BY CODES(#165.7)
  | 
| 20 | PRIMARY SITE | 2;1 | POINTER TO ICDO TOPOGRAPHY FILE (#164) | ************************REQUIRED FIELD************************ ICDO TOPOGRAPHY(#164)
  | 
| 20.1 | PRIMARY SITE CODE | COMPUTED | 
  | 
|
| 21 | CASEFINDING SOURCE | 1;6 | POINTER TO CASEFINDING SOURCE FILE (#166) | ************************REQUIRED FIELD************************ CASEFINDING SOURCE(#166)
  | 
| 21.5 | INFRA/SUPRA | 2;7 | SET | ************************REQUIRED FIELD************************ 
 
  | 
| 21.51 | IRIS/CILIARY BODY | 2;22 | SET | 
 
  | 
| 21.52 | UPPER/LOWER | 24;4 | SET | 
 
  | 
| 22 | HISTOLOGY (ICD-O-2) | 2;3 | POINTER TO ICD-O-2 MORPHOLOGY FILE (#164.1) | ICD-O-2 MORPHOLOGY(#164.1)
  | 
| 22.1 | ICDO HISTOLOGY-CODE | COMPUTED | 
  | 
|
| 22.2 | PAPILLARY/FOLLICULAR | 2;4 | SET | 
 
  | 
| 22.3 | HISTOLOGY (ICD-O-3) | 2.2;3 | POINTER TO ICD-O-3 MORPHOLOGY FILE (#169.3) | ICD-O-3 MORPHOLOGY(#169.3)
  | 
| 22.4 | BEHAVIOR CODE | COMPUTED | 
  | 
|
| 23 | RECONSTRUCTION/RESTORATION | 3;33 | FREE TEXT | 
  | 
| 24 | GRADE/DIFFERENTIATION | 2;5 | POINTER TO GRADE FILE (#164.43) | GRADE(#164.43)
  | 
| 24.1 | GRADE PATH SYSTEM | 2.3;1 | SET | 
 
  | 
| 24.2 | GRADE PATH VALUE | 2.3;2 | SET | 
 
  | 
| 24.3 | GRADE CLINICAL | 2.3;12 | FREE TEXT | 
  | 
| 24.4 | GRADE PATHOLOGICAL | 2.3;13 | FREE TEXT | 
  | 
| 24.5 | GRADE POST THERAPY PATH (YP) | 2.3;14 | FREE TEXT | 
  | 
| 24.6 | GRADE POST THERAPY CLIN (YC) | 2.3;15 | FREE TEXT | 
  | 
| 25 | TNM FORM ASSIGNED | 7;7 | FREE TEXT | 
  | 
| 25.1 | TUMOR MARKER 1 | 24;2 | POINTER TO TUMOR MARKERS FILE (#164.15) | TUMOR MARKERS(#164.15)
  | 
| 25.2 | TUMOR MARKER 2 | 24;3 | POINTER TO TUMOR MARKERS FILE (#164.15) | TUMOR MARKERS(#164.15)
  | 
| 25.3 | TUMOR MARKER 3 | 24;7 | POINTER TO TUMOR MARKERS FILE (#164.15) | TUMOR MARKERS(#164.15)
  | 
| 26 | DIAGNOSTIC CONFIRMATION | 2;6 | SET | 
 
  | 
| 27 | HISTO-MORPHOLOGY | COMPUTED | 
  | 
|
| 28 | LATERALITY | 2;8 | SET | 
 
  | 
| 29 | TUMOR SIZE | 2;9 | NUMBER | 
  | 
| 29.1 | TUMOR SIZE/EXT EVAL (CS) | CS;1 | FREE TEXT | 
  | 
| 29.2 | TUMOR SIZE (CS) | CS1;10 | FREE TEXT | 
  | 
| 29.3 | TUMOR SIZE SUMMARY | 2.1;20 | NUMBER | 
  | 
| 29.4 | TUMOR SIZE CLINICAL | 2.1;21 | NUMBER | 
  | 
| 29.5 | TUMOR SIZE PATHOLOGIC | 2.1;22 | NUMBER | 
  | 
| 29.9 | EXTENSION LIST USED | COMPUTED | 
  | 
|
| 30 | EXTENSION | 2;10 | NUMBER | 
  | 
| 30.1 | PATHOLOGIC EXTENSION | 2.2;2 | NUMBER | 
  | 
| 30.2 | EXTENSION (CS) | CS;11 | FREE TEXT | 
  | 
| 30.5 | PERIPHERAL BLOOD INVOLVEMENT | 24;5 | SET | 
 
  | 
| 30.9 | LYMPH NODE LIST USED | COMPUTED | 
  | 
|
| 31 | LYMPH NODES | 2;11 | NUMBER | 
  | 
| 31.1 | LYMPH NODES (CS) | CS;12 | FREE TEXT | 
  | 
| 32 | REGIONAL LYMPH NODES POSITIVE | 2;12 | NUMBER | 
  | 
| 32.1 | LYMPH NODES EVAL (CS) | CS;2 | FREE TEXT | 
  | 
| 33 | REGIONAL LYMPH NODES EXAMINED | 2;13 | NUMBER | 
  | 
| 33.1 | #NODES EXAMINED | COMPUTED | 
  | 
|
| 34 | SITE OF DISTANT METASTASIS #1 | 2;14 | SET | 
 
  | 
| 34.1 | SITE OF DISTANT METASTASIS #2 | 2;15 | SET | 
 
  | 
| 34.2 | SITE OF DISTANT METASTASIS #3 | 2;16 | SET | 
 
  | 
| 34.3 | METS AT DX (CS) | CS;3 | FREE TEXT | 
  | 
| 34.31 | METS AT DX-BONE | CS1;20 | SET | 
 
  | 
| 34.32 | METS AT DX-BRAIN | CS1;21 | SET | 
 
  | 
| 34.33 | METS AT DX-LIVER | CS1;22 | SET | 
 
  | 
| 34.34 | METS AT DX-LUNG | CS1;23 | SET | 
 
  | 
| 34.35 | METS AT DX-DISTANT LN | CS1;24 | SET | 
 
  | 
| 34.36 | METS AT DX-OTHER | CS1;25 | SET | 
 
  | 
| 34.4 | METS EVAL (CS) | CS;4 | FREE TEXT | 
  | 
| 35 | SEER SUMMARY STAGE 2000 | 2;17 | SET | 
 
  | 
| 35.1 | SEER SUMMARY STAGE ABBREVIATED | COMPUTED | 
  | 
|
| 36 | AJCC STAGING BASIS | 2;18 | SET | 
 
  | 
| 37 | TNM CLINICAL | COMPUTED | 
  | 
|
| 37.1 | CLINICAL T | 2;25 | FREE TEXT | 
  | 
| 37.2 | CLINICAL N | 2;26 | FREE TEXT | 
  | 
| 37.3 | CLINICAL M | 2;27 | FREE TEXT | 
  | 
| 37.9 | AUTOMATIC STAGING OVERRIDDEN | 24;1 | SET | 
 
  | 
| 38 | STAGE GROUP CLINICAL | 2;20 | FREE TEXT | 
  | 
| 38.1 | GP-I AJCC SUMMARY STAGE | COMPUTED | 
  | 
|
| 38.2 | GP-II AJCC SUMMARY STAGE | COMPUTED | 
  | 
|
| 38.3 | GP-III AJCC SUMMARY STAGE | COMPUTED | 
  | 
|
| 38.4 | GP-IV AJCC SUMMARY STAGE | COMPUTED | 
  | 
|
| 38.5 | STAGE GROUPING-AJCC | 2;28 | SET | 
 
  | 
| 39 | OTHER STAGING SYSTEM | 2;21 | POINTER TO OTHER STAGING FOR ONCOLOGY FILE (#164.3) | OTHER STAGING FOR ONCOLOGY(#164.3)
  | 
| 40 | STAGE GROUP BEST | COMPUTED | 
  | 
|
| 40.1 | TNM BEST | COMPUTED | 
  | 
|
| 40.2 | STAGED BY | COMPUTED | 
  | 
|
| 41 | ASSOCIATED WITH HIV | 2;23 | SET | 
 
  | 
| 42 | TREATMENT ABBREVIATED | COMPUTED | 
  | 
|
| 43 | TREATMENT | COMPUTED | 
  | 
|
| 44 | TNM FORM COMPLETED | 7;14 | FREE TEXT | 
  | 
| 44.1 | SSF1 | CS;5 | FREE TEXT | 
  | 
| 44.101 | SSF10 | CS2;4 | FREE TEXT | 
  | 
| 44.11 | SSF11 | CS2;5 | FREE TEXT | 
  | 
| 44.12 | SSF12 | CS2;6 | FREE TEXT | 
  | 
| 44.13 | SSF13 | CS2;7 | FREE TEXT | 
  | 
| 44.14 | SSF14 | CS2;8 | FREE TEXT | 
  | 
| 44.15 | SSF15 | CS2;9 | FREE TEXT | 
  | 
| 44.16 | SSF16 | CS2;10 | FREE TEXT | 
  | 
| 44.17 | SSF17 | CS2;11 | FREE TEXT | 
  | 
| 44.18 | SSF18 | CS2;12 | FREE TEXT | 
  | 
| 44.19 | SSF19 | CS2;13 | FREE TEXT | 
  | 
| 44.2 | SSF2 | CS;6 | FREE TEXT | 
  | 
| 44.201 | SSF20 | CS2;14 | FREE TEXT | 
  | 
| 44.21 | SSF21 | CS2;15 | FREE TEXT | 
  | 
| 44.22 | SSF22 | CS2;16 | FREE TEXT | 
  | 
| 44.23 | SSF23 | CS2;17 | FREE TEXT | 
  | 
| 44.24 | SSF24 | CS2;18 | FREE TEXT | 
  | 
| 44.25 | SSF25 | CS2;19 | FREE TEXT | 
  | 
| 44.3 | SSF3 | CS;7 | FREE TEXT | 
  | 
| 44.4 | SSF4 | CS;8 | FREE TEXT | 
  | 
| 44.5 | SSF5 | CS;9 | FREE TEXT | 
  | 
| 44.6 | SSF6 | CS;10 | FREE TEXT | 
  | 
| 44.7 | SSF7 | CS2;1 | FREE TEXT | 
  | 
| 44.8 | SSF8 | CS2;2 | FREE TEXT | 
  | 
| 44.9 | SSF9 | CS2;3 | FREE TEXT | 
  | 
| 45 | PERFORMANCE STATUS | 2;24 | SET | 
 
  | 
| 46 | CAP PROTOCOL REVIEW | 7;19 | SET | 
 
  | 
| 47 | CAP TEXT | 7;20 | FREE TEXT | 
  | 
| 48 | OTHER PRIMARY SITES | COMPUTED | 
  | 
|
| 49 | DATE 1ST CRS RX COC | COMPUTED | 
  | 
|
| 49.1 | FIRST TREATMENT DT-DATE DX | COMPUTED | 
  | 
|
| 49.9 | DATE INITIAL RX SEER | COMPUTED | 
  | 
|
| 50 | MOST DEFINITIVE SURG DATE | 3;1 | DATE | 
  | 
| 50.1 | SURGERY HOSPITAL | 3;2 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
  | 
| 50.2 | SURGERY OF PRIMARY @FAC (R) | 3.1;7 | FREE TEXT | 
  | 
| 50.3 | MOST DEFINITIVE SURG @FAC DATE | 3.1;8 | DATE | 
  | 
| 51 | DATE RADIATION STARTED | 3;4 | DATE | 
  | 
| 51.1 | RADIATION HOSPITAL | 3;5 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
  | 
| 51.2 | RADIATION | 3;6 | SET | 
 
  | 
| 51.3 | RADIATION/SURGERY SEQUENCE | 3;7 | SET | 
 
  | 
| 51.4 | RADIATION @FACILITY | 3.1;12 | SET | 
 
  | 
| 51.5 | RADIATION @FACILITY DATE | 3.1;13 | DATE | 
  | 
| 52 | RADIATION THERAPY TO CNS DATE | 3;8 | DATE | 
  | 
| 52.1 | RADIATION THERAPY TO CNS HOSP | 3;9 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
  | 
| 52.2 | RADIATION THERAPY TO CNS | 3;10 | SET | 
 
  | 
| 53 | CHEMOTHERAPY DATE | 3;11 | DATE | 
  | 
| 53.1 | CHEMOTHERAPY HOSPITAL | 3;12 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
  | 
| 53.2 | CHEMOTHERAPY | 3;13 | SET | 
 
  | 
| 53.3 | CHEMOTHERAPY @FAC | 3.1;14 | SET | 
 
  | 
| 53.4 | CHEMOTHERAPY @FAC DATE | 3.1;15 | DATE | 
  | 
| 54 | HORMONE THERAPY DATE | 3;14 | DATE | 
  | 
| 54.1 | HORMONE THERAPY HOSPITAL | 3;15 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
  | 
| 54.2 | HORMONE THERAPY | 3;16 | SET | 
 
  | 
| 54.3 | HORMONE THERAPY @FAC | 3.1;16 | SET | 
 
  | 
| 54.4 | HORMONE THERAPY @FAC DATE | 3.1;17 | DATE | 
  | 
| 55 | IMMUNOTHERAPY DATE | 3;17 | DATE | 
  | 
| 55.1 | IMMUNOTHERAPY HOSPITAL | 3;18 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
  | 
| 55.2 | IMMUNOTHERAPY | 3;19 | SET | 
 
  | 
| 55.3 | IMMUNOTHERAPY @FAC | 3.1;18 | SET | 
 
  | 
| 55.4 | IMMUNOTHERAPY @FAC DATE | 3.1;19 | DATE | 
  | 
| 56 | NUMBER OF TXS TO THIS VOLUME | 3;20 | NUMBER | 
  | 
| 57 | OTHER TREATMENT START DATE | 3;23 | DATE | 
  | 
| 57.1 | OTHER TREATMENT HOSPITAL | 3;24 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
  | 
| 57.2 | OTHER TREATMENT | 3;25 | SET | 
 
  | 
| 57.3 | OTHER TREATMENT @FAC | 3.1;20 | SET | 
 
  | 
| 57.4 | OTHER TREATMENT @FACILITY DATE | 3.1;21 | DATE | 
  | 
| 58 | REASON NO SURGERY OF PRIMARY | 3;26 | SET | 
 
  | 
| 58.1 | SURGICAL DX/STAGING PROC | 3;27 | FREE TEXT | 
  | 
| 58.2 | SURGERY OF PRIMARY (R) | 3;38 | NUMBER | 
  | 
| 58.3 | SURGICAL DX/STAGING PROC DATE | 3;31 | DATE | 
  | 
| 58.4 | SURG DX/STAGING PROC @FAC | 3.1;5 | FREE TEXT | 
  | 
| 58.5 | SURG DX/STAGING PROC @FAC DATE | 3.1;6 | DATE | 
  | 
| 58.6 | RX SUMM--SURG PRIMSITE 03-2022 | 3.1;29 | FREE TEXT | 
  | 
| 58.7 | RX HOSP--SURG PRIMSITE 03-2022 | 3.1;30 | FREE TEXT | 
  | 
| 58.8 | RX HOSP--SURG PRIM SITE 2023 | 3.2;8 | FREE TEXT | 
  | 
| 58.9 | RX SUMM--SURG PRIM SITE 2023 | 3.2;9 | FREE TEXT | 
  | 
| 59 | SURGICAL MARGINS | 3;28 | SET | 
 
  | 
| 60 | SUBSEQUENT COURSE OF TREATMENT | 4;0 | DATE Multiple #165.51 | 165.51
  | 
| 61 | PID# | COMPUTED | 
  | 
|
| 62 | QA SELECTED | 7;4 | SET | 
 
  | 
| 63 | QA REVIEW | 7;8 | SET | 
 
  | 
| 64 | QA DATE | 7;9 | DATE | 
  | 
| 64.1 | QA REVIEWER | 7;18 | POINTER TO NEW PERSON FILE (#200) | NEW PERSON(#200)
  | 
| 64.2 | QA FINDINGS | 28;0 | WORD-PROCESSING #165.54 | 
  | 
| 65 | PHYSICIAN'S STAGE | 7;10 | FREE TEXT | 
  | 
| 66 | PHYSICIAN STAGING | 7;11 | POINTER TO ONCOLOGY CONTACT FILE (#165) | ONCOLOGY CONTACT(#165)
  | 
| 67 | ACOS # | COMPUTED | 
  | 
|
| 68 | STATE HOSPITAL # | COMPUTED | 
  | 
|
| 69 | MULTIPLE TUMORS | 2;31 | NUMBER | 
  | 
| 69.1 | FAMILY HISTORY | 2;32 | SET | 
 
  | 
| 69.2 | DIFFUSE RETINAL INVOLVEMENT | 3;30 | SET | 
 
  | 
| 69.3 | MULTIMODALITY THERAPY (CLIN) | 7;16 | SET | 
 
  | 
| 69.4 | MULTIMODALITY THERAPY | 7;17 | SET | 
 
  | 
| 70 | DATE OF FIRST RECURRENCE | 5;1 | DATE | 
  | 
| 71 | TYPE OF FIRST RECURRENCE | 5;2 | POINTER TO TYPE OF RECURRENCE FILE (#160.12) | TYPE OF RECURRENCE(#160.12)
  | 
| 71.1 | DISTANT SITE 1 | 5;3 | SET | 
 
  | 
| 71.2 | DISTANT SITE 2 | 5;4 | SET | 
 
  | 
| 71.3 | DISTANT SITE 3 | 5;5 | SET | 
 
  | 
| 71.4 | OTHER TYPE OF FIRST RECURRENCE | 5;6 | POINTER TO TYPE OF RECURRENCE FILE (#160.12) | TYPE OF RECURRENCE(#160.12)
  | 
| 72 | SUBSEQUENT RECURRENCES | 23;0 | DATE Multiple #165.572 | 165.572
  | 
| 73 | TUMOR STATUS | TS;0 | DATE Multiple #165.573 | 165.573
  | 
| 74 | SURGICAL APPROACH (R) | 3;34 | NUMBER | 
  | 
| 75 | REASON FOR NO RADIATION | 3;35 | SET | 
 
  | 
| 76 | REASON FOR NO CHEMOTHERAPY | 3;36 | SET | 
 
  | 
| 77 | REASON FOR NO HORMONE THERAPY | 3;37 | SET | 
 
  | 
| 78 | CONVERTED | 24;6 | SET | 
 
  | 
| 78.1 | CONVERTED STAGED BY FIELDS | 25;19 | SET | 
 
  | 
| 78.2 | CONVERTED TNM FIELDS | 25;20 | SET | 
 
  | 
| 79 | SCREENING DATE | 0;24 | DATE | 
  | 
| 80 | RADIATION TREATMENT | 6;0 | Multiple #165.52 | 165.52
  | 
| 81 | COMPLETED BY | 7;12 | FREE TEXT | 
  | 
| 82 | REVIEWED BY CANCER COMMITTEE | 7;13 | FREE TEXT | 
  | 
| 83 | AFIP/JPC SUBMISSION | 0;21 | SET | 
 
  | 
| 84 | PCE INDICATOR | 7;15 | SET | 
 
  | 
| 85 | PATHOLOGIC T | 2.1;1 | FREE TEXT | 
  | 
| 86 | PATHOLOGIC N | 2.1;2 | FREE TEXT | 
  | 
| 87 | PATHOLOGIC M | 2.1;3 | FREE TEXT | 
  | 
| 88 | STAGE GROUP PATHOLOGIC | 2.1;4 | FREE TEXT | 
  | 
| 89 | STAGED BY (PATHOLOGIC STAGE) | 2.1;5 | POINTER TO ONCOLOGY STAGED BY CODES FILE (#165.7) | ONCOLOGY STAGED BY CODES(#165.7)
  | 
| 89.1 | TNM PATHOLOGIC | COMPUTED | 
  | 
|
| 90 | DATE CASE COMPLETED | 7;1 | DATE | 
  | 
| 91 | ABSTRACT STATUS | 7;2 | SET | 
 
  | 
| 92 | ABSTRACTED BY | 7;3 | POINTER TO NEW PERSON FILE (#200) | ************************REQUIRED FIELD************************ NEW PERSON(#200)
  | 
| 93 | OTHER T | 2.1;6 | FREE TEXT | 
  | 
| 94 | REPORTING DATE | 7;5 | DATE | 
  | 
| 95 | LAST TUMOR STATUS | 7;6 | POINTER TO PRIMARY CANCER STATUS CODE FILE (#164.42) | PRIMARY CANCER STATUS CODE(#164.42)
  | 
| 95.1 | V STATUS/LAST TUMOR STATUS | COMPUTED | 
  | 
|
| 96 | PSA DATE | PRO2;50 | FREE TEXT | 
  | 
| 97 | ABSTRACT INCOMPLETE | BOOLEAN COMPUTED | 
  | 
|
| 98 | OTHER N | 2.1;7 | FREE TEXT | 
  | 
| 99 | OTHER M | 2.1;8 | FREE TEXT | 
  | 
| 100 | TEXT-PRIMARY SITE TITLE | 8;1 | FREE TEXT | 
  | 
| 101 | TEXT-HISTOLOGY TITLE | 8;2 | FREE TEXT | 
  | 
| 102 | DRE +/- | 24;10 | SET | 
 
  | 
| 103 | TEXT-DX PROC-OP | 9;0 | WORD-PROCESSING #165.5103 | 
  | 
| 104 | TEXT-DX PROC-PE | 10;0 | WORD-PROCESSING #165.5104 | 
  | 
| 105 | TEXT-DX PROC-X-RAY/SCAN | 11;0 | WORD-PROCESSING #165.5105 | 
  | 
| 106 | TEXT-DX PROC-SCOPES | 12;0 | WORD-PROCESSING #165.5106 | 
  | 
| 107 | TEXT-DX PROC-PATH | 13;0 | WORD-PROCESSING #165.5107 | 
  | 
| 108 | RX TEXT-SURGERY | 14;0 | WORD-PROCESSING #165.5108 | 
  | 
| 109 | RX TEXT-RADIATION | 15;0 | WORD-PROCESSING #165.5109 | 
  | 
| 110 | RX TEXT-RADIATION OTHER | 16;0 | WORD-PROCESSING #165.53 | 
  | 
| 111 | RX TEXT-CHEMO | 17;0 | WORD-PROCESSING #165.5111 | 
  | 
| 112 | RX TEXT-HORMONE | 18;0 | WORD-PROCESSING #165.5112 | 
  | 
| 113 | TEXT-REMARKS | 19;0 | WORD-PROCESSING #165.5113 | 
  | 
| 114 | RX TEXT-BRM | 20;0 | WORD-PROCESSING #165.5114 | 
  | 
| 115 | RX TEXT-OTHER | 21;0 | WORD-PROCESSING #165.5115 | 
  | 
| 116 | TEXT-DX PROC-LAB TESTS | 22;0 | WORD-PROCESSING #165.5116 | 
  | 
| 117 | OTHER STAGE GROUP | 2.1;9 | FREE TEXT | 
  | 
| 118 | STAGED BY (OTHER STAGE) | 2.1;10 | SET | 
 
  | 
| 119 | SCREENING RESULT | 0;25 | SET | 
 
  | 
| 120 | PRESENTATION AT CANCER CONF | 0;26 | SET | 
 
  | 
| 121 | DATE OF CANCER CONF | 0;27 | DATE | 
  | 
| 122 | REFERRAL TO SUPPORT SERVICES | 0;28 | SET | 
 
  | 
| 123 | INPATIENT/OUTPATIENT STATUS | 0;23 | SET | 
 
  | 
| 124 | DATE OF NO TREATMENT | 2.1;11 | DATE | 
  | 
| 125 | RADIATION TREATMENT VOLUME | 3;21 | POINTER TO RADIATION TREATMENT VOLUME FILE (#164.7) | RADIATION TREATMENT VOLUME(#164.7)
  | 
| 126 | LOCATION OF RADIATION TX | 3;22 | SET | 
 
  | 
| 127 | INTENT OF RADIATION | 3;29 | SET | 
 
  | 
| 128 | RADIATION COMPLETION STATUS | 3;39 | POINTER TO RADIATION COMPLETION STATUS FILE (#164.8) | RADIATION COMPLETION STATUS(#164.8)
  | 
| 129 | RADIATION AUXILIARY VOLUME | 3.1;1 | POINTER TO RADIATION TREATMENT VOLUME FILE (#164.7) | RADIATION TREATMENT VOLUME(#164.7)
  | 
| 130 | RADIATION AUXILIARY DATE | 3.1;2 | DATE | 
  | 
| 131 | RADIATION AUXILIARY TEXT | 15.1;0 | WORD-PROCESSING #165.5131 | 
  | 
| 132 | RADIATION LOCAL CONTROL STATUS | 3.1;3 | SET | 
 
  | 
| 133 | YEAR PUT ON PROTOCOL | 3.1;4 | FREE TEXT | 
  | 
| 134 | CLINICAL RISK FACTORS | 2.1;12 | SET | 
 
  | 
| 135 | PATHOLOGIC RISK FACTORS | 2.1;13 | SET | 
 
  | 
| 136 | SERUM TUMOR MARKERS | 24;8 | SET | 
 
  | 
| 137 | DATE OF 1ST POSITIVE BIOPSY | 2.2;1 | DATE | 
  | 
| 138 | SCOPE OF LN SURGERY (R) | 3;40 | NUMBER | 
  | 
| 138.1 | SCOPE OF LN SURGERY @FAC (R) | 3.1;9 | FREE TEXT | 
  | 
| 138.2 | SCOPE OF LN SURGERY DATE | 3.1;22 | DATE | 
  | 
| 138.3 | SCOPE OF LN SURGERY @FAC DATE | 3.1;23 | DATE | 
  | 
| 138.4 | SCOPE OF LN SURGERY (F) | 3.1;31 | SET | 
 
  | 
| 138.5 | SCOPE OF LN SURGERY @FAC (F) | 3.1;32 | SET | 
 
  | 
| 139 | SURG PROC/OTHER SITE (R) | 3;41 | NUMBER | 
  | 
| 139.1 | SURG PROC/OTHER SITE @FAC (R) | 3.1;10 | FREE TEXT | 
  | 
| 139.2 | SURG PROC/OTHER SITE DATE | 3.1;24 | DATE | 
  | 
| 139.3 | SURG PROC/OTHER SITE @FAC DATE | 3.1;25 | DATE | 
  | 
| 139.4 | SURG PROC/OTHER SITE (F) | 3.1;33 | SET | 
 
  | 
| 139.5 | SURG PROC/OTHER SITE @FAC (F) | 3.1;34 | SET | 
 
  | 
| 139.6 | METS SITE RESECTED | 3.1;41 | SET | 
 
  | 
| 139.7 | METS SITE RESECTED DATE | 3.2;1 | DATE | 
  | 
| 140 | NUMBER OF LN REMOVED (R) | 3;42 | NUMBER | 
  | 
| 140.1 | NUMBER OF LN REMOVED @FAC (R) | 3.1;11 | FREE TEXT | 
  | 
| 141 | BIOPSY PROCEDURE | 2.1;14 | NUMBER | 
  | 
| 142 | GUIDANCE | 2.1;15 | NUMBER | 
  | 
| 143 | PALPABILITY OF PRIMARY | 2.1;16 | SET | 
 
  | 
| 144 | FIRST DETECTED BY | 2.1;17 | SET | 
 
  | 
| 145 | APPROACH FOR BIOPSY OF PRIMARY | 2.1;18 | SET | 
 
  | 
| 146 | BIOPSY OF OTHER THAN PRIMARY | 2.1;19 | SET | 
 
  | 
| 147 | CENSUS TRACT | 0;29 | FREE TEXT | 
  | 
| 148 | OTHER CANCER | 0;30 | SET | 
 
  | 
| 148.1 | CANCER #1 | 0;31 | POINTER TO SITE-GROUP FOR ONCOLOGY FILE (#164.2) | SITE-GROUP FOR ONCOLOGY(#164.2)
  | 
| 148.2 | CANCER #2 | 0;32 | POINTER TO SITE-GROUP FOR ONCOLOGY FILE (#164.2) | SITE-GROUP FOR ONCOLOGY(#164.2)
  | 
| 148.3 | CANCER #3 | 0;33 | POINTER TO SITE-GROUP FOR ONCOLOGY FILE (#164.2) | SITE-GROUP FOR ONCOLOGY(#164.2)
  | 
| 148.4 | CANCER #4 | 0;34 | POINTER TO SITE-GROUP FOR ONCOLOGY FILE (#164.2) | SITE-GROUP FOR ONCOLOGY(#164.2)
  | 
| 149 | LYMPH-VASCULAR INVASION (L) | 2;19 | SET | 
 
  | 
| 150 | FOLLOW-UP HISTORY | COMPUTED | 
  | 
|
| 151 | VENOUS INVASION (V) | 2;29 | SET | 
 
  | 
| 152 | DATE SYSTEMIC THERAPY STARTED | COMPUTED | 
  | 
|
| 153 | HEMA TRANS/ENDOCRINE PROC | 3.1;36 | POINTER TO HEMATOLOGIC TRANSPLANT/ENDOCRINE PROCEDURES FILE (#167) | HEMATOLOGIC TRANSPLANT/ENDOCRINE PROCEDURES(#167)
  | 
| 153.1 | HEMA TRANS/ENDOCRINE PROC DATE | 3.1;35 | DATE | 
  | 
| 153.2 | HEMA TRANS/ENDOCRINE PROC @FAC | 3.2;2 | POINTER TO HEMATOLOGIC TRANSPLANT/ENDOCRINE PROCEDURES FILE (#167) | HEMATOLOGIC TRANSPLANT/ENDOCRINE PROCEDURES(#167)
  | 
| 153.3 | HEMA TRANS/ENDOCRINE PR@FAC DT | 3.2;3 | DATE | 
  | 
| 154 | PAIN ASSESSMENT | 3.1;37 | SET | 
 
  | 
| 155 | DATE OF FIRST CONTACT | 0;35 | DATE | ************************REQUIRED FIELD************************ 
  | 
| 156 | DRE DATE | 24;11 | FREE TEXT | 
  | 
| 157 | ELAPSED DAYS TO COMPLETION | COMPUTED | 
  | 
|
| 157.1 | ELAPSED MONTHS TO COMPLETION | COMPUTED | 
  | 
|
| 159 | AMBIGUOUS TERMINOLOGY DX | 24;12 | SET | 
 
  | 
| 160 | DERIVED AJCC-6 T | CS1;1 | FREE TEXT | 
  | 
| 160.7 | DERIVED AJCC-7 T | CS1;13 | FREE TEXT | 
  | 
| 161 | DERIVED AJCC-6 T DESCRIPTOR | CS1;2 | SET | 
 
  | 
| 161.7 | DERIVED AJCC-7 T DESCRIPTOR | CS1;14 | SET | 
 
  | 
| 162 | DERIVED AJCC-6 N | CS1;3 | FREE TEXT | 
  | 
| 162.7 | DERIVED AJCC-7 N | CS1;15 | FREE TEXT | 
  | 
| 163 | DERIVED AJCC-6 N DESCRIPTOR | CS1;4 | SET | 
 
  | 
| 163.7 | DERIVED AJCC-7 N DESCRIPTOR | CS1;16 | SET | 
 
  | 
| 164 | DERIVED AJCC-6 M | CS1;5 | FREE TEXT | 
  | 
| 164.7 | DERIVED AJCC-7 M | CS1;17 | FREE TEXT | 
  | 
| 165 | DERIVED AJCC-6 M DESCRIPTOR | CS1;6 | SET | 
 
  | 
| 165.7 | DERIVED AJCC-7 M DESCRIPTOR | CS1;18 | SET | 
 
  | 
| 166 | DERIVED AJCC-6 STAGE GROUP | CS1;7 | FREE TEXT | 
  | 
| 166.7 | DERIVED AJCC-7 STAGE GROUP | CS1;19 | FREE TEXT | 
  | 
| 167 | DERIVED SS1977 | CS1;8 | SET | 
 
  | 
| 168 | DERIVED SS2000 | CS1;9 | SET | 
 
  | 
| 169 | CS VERSION DERIVED | CS1;11 | FREE TEXT | 
  | 
| 169.1 | CS VERSION INPUT ORIGINAL | CS1;12 | FREE TEXT | 
  | 
| 170 | DATE FIRST SURGICAL PROCEDURE | 3.1;38 | DATE | 
  | 
| 171 | DATE OF FIRST SYMPTOMS | 2.2;4 | FREE TEXT | 
  | 
| 172 | DATE START OF WORKUP ORDERED | 2.2;5 | FREE TEXT | 
  | 
| 173 | DATE WORKUP STARTED | 2.2;6 | FREE TEXT | 
  | 
| 174 | BLOOD IN SPUTUM PER PT | 2.2;7 | SET | 
 
  | 
| 174.1 | DATE OF BLOOD IN SPUTUM PER PT | 2.2;18 | FREE TEXT | 
  | 
| 175 | CHEST X-RAY | 2.2;8 | SET | 
 
  | 
| 175.1 | DATE OF CHEST X-RAY | 2.2;19 | FREE TEXT | 
  | 
| 176 | CT SCAN | 2.2;9 | SET | 
 
  | 
| 176.1 | DATE OF CT SCAN | 2.2;20 | FREE TEXT | 
  | 
| 177 | BRONCHOSCOPY | 2.2;10 | SET | 
 
  | 
| 177.1 | DATE OF BRONCHOSCOPY | 2.2;21 | FREE TEXT | 
  | 
| 178 | MEDIASTINOSCOPY | 2.2;11 | SET | 
 
  | 
| 178.1 | DATE OF MEDIASTINOSCOPY | 2.2;22 | FREE TEXT | 
  | 
| 179 | PET SCAN | 2.2;12 | SET | 
 
  | 
| 179.1 | DATE OF PET SCAN | 2.2;23 | FREE TEXT | 
  | 
| 180 | CHANGE IN BOWEL HABITS PER PT | 2.2;13 | SET | 
 
  | 
| 180.1 | DATE OF CHANGE IN BOWEL HABITS | 2.2;24 | FREE TEXT | 
  | 
| 181 | FECAL OCCULT BLOOD TEST (FOBT) | 2.2;14 | SET | 
 
  | 
| 181.1 | DATE OF FOBT | 2.2;25 | FREE TEXT | 
  | 
| 182 | BARIUM ENEMA | 2.2;15 | SET | 
 
  | 
| 182.1 | DATE OF BARIUM ENEMA | 2.2;27 | FREE TEXT | 
  | 
| 183 | SIGMOIDOSCOPY | 2.2;16 | SET | 
 
  | 
| 183.1 | DATE OF SIGMOIDOSCOPY | 2.2;28 | FREE TEXT | 
  | 
| 184 | CT OF ABDOMEN/PELVIS | 2.2;17 | SET | 
 
  | 
| 184.1 | DATE OF CT OF ABDOMEN/PELVIS | 2.2;31 | FREE TEXT | 
  | 
| 185 | COLONOSCOPY | 2.2;29 | SET | 
 
  | 
| 185.1 | DATE OF COLONOSCOPY | 2.2;30 | FREE TEXT | 
  | 
| 186 | DYSPNEA | 2.2;32 | SET | 
 
  | 
| 186.1 | DATE OF DYSPNEA | 2.2;33 | FREE TEXT | 
  | 
| 187 | INCREASED COUGH | 2.2;34 | SET | 
 
  | 
| 187.1 | DATE OF INCREASED COUGH | 2.2;35 | FREE TEXT | 
  | 
| 188 | FEVER | 2.2;36 | SET | 
 
  | 
| 188.1 | DATE OF FEVER | 2.2;37 | FREE TEXT | 
  | 
| 189 | NIGHT SWEATS | 2.2;38 | SET | 
 
  | 
| 189.1 | DATE OF NIGHT SWEATS | 2.2;39 | FREE TEXT | 
  | 
| 190 | WEIGHT LOSS PER PT | 2.2;40 | SET | 
 
  | 
| 191 | ULCERATIVE COLITIS (UC) | 2.2;41 | SET | 
 
  | 
| 192 | SPORADIC POLYPS | 2.2;42 | SET | 
 
  | 
| 193 | DATE OF CONCLUSIVE DX | 24;13 | FREE TEXT | 
  | 
| 194 | MULT TUM RPT AS ONE PRIM | 24;14 | POINTER TO TYPE OF MULTIPLE TUMORS FILE (#169) | TYPE OF MULTIPLE TUMORS(#169)
  | 
| 195 | DATE OF MULTIPLE TUMORS | 24;15 | FREE TEXT | 
  | 
| 196 | MULTIPLICITY COUNTER | 24;16 | FREE TEXT | 
  | 
| 197 | EDITS CHECKSUM | EDITS;1 | FREE TEXT | 
  | 
| 197.1 | CHECKSUM VERSION | EDITS;2 | FREE TEXT | 
  | 
| 198 | DATE CASE LAST CHANGED | 7;21 | DATE | 
  | 
| 199 | CASE LAST CHANGED BY | 7;22 | POINTER TO NEW PERSON FILE (#200) | NEW PERSON(#200)
  | 
| 200 | DATE LAST CONTACT | COMPUTED | 
  | 
|
| 201 | SURVIVAL DAYS | COMPUTED | 
  | 
|
| 202 | SURVIVAL MONTHS | COMPUTED | 
  | 
|
| 203 | SURVIVAL (YEARS) | COMPUTED | 
  | 
|
| 204 | WEEKS of FOLLOW-UP | COMPUTED | 
  | 
|
| 205 | OVER-RIDE AGE/SITE/MORPH | OVRD;1 | SET | 
 
  | 
| 206 | OVER-RIDE SEQNO/DXCONF | OVRD;2 | SET | 
 
  | 
| 207 | OVER-RIDE SITE/LAT/SEQNO | OVRD;3 | SET | 
 
  | 
| 208 | OVER-RIDE SURG/DXCONF | OVRD;4 | SET | 
 
  | 
| 209 | OVER-RIDE SITE/TYPE | OVRD;5 | SET | 
 
  | 
| 210 | OVER-RIDE HISTOLOGY | OVRD;6 | SET | 
 
  | 
| 211 | OVER-RIDE REPORT SOURCE | OVRD;7 | SET | 
 
  | 
| 212 | OVER-RIDE ILL-DEFINE SITE | OVRD;8 | SET | 
 
  | 
| 213 | OVER-RIDE LEUK,LYMPHOMA | OVRD;9 | SET | 
 
  | 
| 214 | OVER-RIDE SITE/BEHAVIOR | OVRD;10 | SET | 
 
  | 
| 215 | OVER-RIDE SITE/EOD/DX DT | OVRD;11 | SET | 
 
  | 
| 216 | OVER-RIDE SITE/LAT/EOD | OVRD;12 | SET | 
 
  | 
| 217 | OVER-RIDE SITE/LAT/MORPH | OVRD;13 | SET | 
 
  | 
| 218 | OVER-RIDE SS/NODESPOS | OVRD;14 | SET | 
 
  | 
| 219 | OVER-RIDE SS/TNM-N | OVRD;15 | SET | 
 
  | 
| 220 | OVER-RIDE SS/TNM-M | OVRD;16 | SET | 
 
  | 
| 221 | OVER-RIDE SS/DISMET1 | OVRD;17 | SET | 
 
  | 
| 222 | OVER-RIDE ACSN/CLASS/SEQ | OVRD;18 | SET | 
 
  | 
| 223 | OVER-RIDE HOSPSEQ/DXCONF | OVRD;19 | SET | 
 
  | 
| 224 | OVER-RIDE COC-SITE/TYPE | OVRD;20 | SET | 
 
  | 
| 225 | OVER-RIDE HOSPSEQ/SITE | OVRD;21 | SET | 
 
  | 
| 226 | OVER-RIDE SITE/TNM-STGGRP | OVRD;22 | SET | 
 
  | 
| 227 | PERFORMANCE STATUS AT DX | 1;7 | SET | 
 
  | 
| 228 | TREATMENT GUIDELINE #1 | 24;17 | SET | 
 
  | 
| 229 | TREATMENT GUIDELINE #2 | 24;18 | SET | 
 
  | 
| 230 | TREATMENT GUIDELINE #3 | 24;19 | SET | 
 
  | 
| 231 | TREATMENT GUIDELINE LOCATION | 24;20 | FREE TEXT | 
  | 
| 232 | TREATMENT GUIDELINE DOC DATE | 24;21 | DATE | 
  | 
| 233 | INPATIENT STATUS | 2.3;3 | SET | 
 
  | 
| 234 | RX HOSP--SURG APP 2010 | 2.3;4 | SET | 
 
  | 
| 235 | TREATMENT STATUS | 2.3;5 | SET | 
 
  | 
| 236 | DATE CASE INITIATED | 2.3;6 | DATE | 
  | 
| 237 | FEE BASIS | 2.3;7 | SET | 
 
  | 
| 237.1 | FEE BASIS LOCATION | 2.3;11 | FREE TEXT | 
  | 
| 238 | OUTSIDE SLIDES REVIEWED | 2.3;8 | SET | 
 
  | 
| 239 | MITOTIC RATE | 2.3;9 | SET | 
 
  | 
| 240 | CS SCHEMA DISCRIMINATOR | CS3;1 | FREE TEXT | 
  | 
| 241 | TNM CLIN DESCRIPTOR | 24;22 | SET | 
 
  | 
| 242 | TNM PATH DESCRIPTOR | 24;23 | SET | 
 
  | 
| 244 | INITIATED BY | 2.3;10 | POINTER TO NEW PERSON FILE (#200) | NEW PERSON(#200)
  | 
| 245 | NEOADJUVANT THERAPY (PRE-2021) | 3.1;40 | SET | 
 
  | 
| 245.1 | NEOADJUVANT THERAPY | EOD;5 | SET | 
 
  | 
| 245.2 | NEOADJUVANT THERAPY-CLIN RESP | EOD;6 | SET | 
 
  | 
| 245.3 | NEOADJUVANT THERAPY-TX EFFECT | EOD;7 | NUMBER | 
  | 
| 247 | CS REVIEW REQUIRED | CS3;2 | SET | 
 
  | 
| 248 | NOTE TITLE | 25;1 | FREE TEXT | 
  | 
| 249 | NOTE DATE | 25;2 | DATE | 
  | 
| 250 | GLEASON SCORE PATH - OBSOLETE | 25;3 | FREE TEXT | 
  | 
| 251 | NSLC STAGE 1-3 PATH LN STAGING | PM;1 | SET | 
 
  | 
| 252 | REASON FOR NO LN BIOPSY | PM;2 | SET | 
 
  | 
| 253 | DATE OF SURGERY CONSULT | PM;3 | DATE | 
  | 
| 254 | INTENT OF SURGERY | PM;4 | SET | 
 
  | 
| 255 | DATE ONCOLOGY CONSULT ORDERED | PM;5 | DATE | 
  | 
| 256 | DATE ONCOLOGY CONSULT DONE | PM;6 | DATE | 
  | 
| 257 | CHEMOTHERAPY RECOMMENDED | PM;7 | SET | 
 
  | 
| 258 | INTENT OF CHEMOTHERAPY | PM;8 | SET | 
 
  | 
| 259 | TYPE OF CHEMOTHERAPY | PM;9 | SET | 
 
  | 
| 260 | REASON RADIATION STOPPED | PM;10 | SET | 
 
  | 
| 261 | DOC FOR NO PLAT-BASED CHEMO | PM;11 | SET | 
 
  | 
| 262 | MULTIMODALITY RADIATION TYPE | PM;12 | SET | 
 
  | 
| 263 | REASON HORMONE THERAPY STOPPED | PM;28 | SET | 
 
  | 
| 264 | DATE HOSPICE CONSULT INITIATED | PM;14 | DATE | 
  | 
| 265 | DATE HOSPICE CONSULT COMPLETED | PM;15 | DATE | 
  | 
| 266 | DATE HOSPICE CARE INITIATED | PM;16 | DATE | 
  | 
| 267 | EGFR MUTATION TESTING | PM;17 | SET | 
 
  | 
| 268 | EGFR MUTATION 1 | PM;18 | SET | 
 
  | 
| 269 | EGFR MUTATION 2 | PM;19 | SET | 
 
  | 
| 270 | PREOP OBSTRUCTING LESION | PM;13 | SET | 
 
  | 
| 271 | ONCOLOGY REFERRAL | PM;20 | SET | 
 
  | 
| 272 | DATE CHEMOTHERAPY RECOMMENDED | PM;21 | DATE | 
  | 
| 273 | ANTI-EGFR MoAB THERAPY | PM;22 | SET | 
 
  | 
| 274 | PERIRECTAL LN INVOLVEMENT | PM;23 | SET | 
 
  | 
| 275 | RISK OF RECURRENCE | PM;24 | SET | 
 
  | 
| 276 | ANDROGEN DEPRIVATION THERAPY | PM;25 | SET | 
 
  | 
| 277 | DATE ADT INITIATED | PM;26 | DATE | 
  | 
| 278 | NON-ADT CHEMOTHERAPY | PM;27 | SET | 
 
  | 
| 279 | CLINICAL TRIALS DISCUSSION | 25;4 | SET | 
 
  | 
| 280 | CLIN TNM DOCUMENTATION PRE-TX | 25;5 | SET | 
 
  | 
| 280.1 | CL TNM DOCUMENTATION LOCATION | 25;7 | FREE TEXT | 
  | 
| 280.2 | CL TNM DOCUMENTATION DATE | 25;8 | DATE | 
  | 
| 281 | TX GUIDELINES DISCUSSION | 25;6 | SET | 
 
  | 
| 282 | VACCR EXTRACT INDICATOR | EDITS;3 | SET | 
 
  | 
| 283 | CS FIELD NEEDING REVIEW | CS3;3 | FREE TEXT | 
  | 
| 284 | UDF1 | 25;9 | FREE TEXT | 
  | 
| 284.1 | UDF2 | 25;10 | FREE TEXT | 
  | 
| 284.2 | UDF3 | 25;11 | FREE TEXT | 
  | 
| 284.3 | UDF4 | 25;12 | FREE TEXT | 
  | 
| 284.4 | UDF5 | 25;13 | FREE TEXT | 
  | 
| 284.5 | UDF6 | 25;14 | FREE TEXT | 
  | 
| 284.6 | UDF7 | 25;15 | FREE TEXT | 
  | 
| 284.7 | UDF8 | 25;16 | FREE TEXT | 
  | 
| 284.8 | UDF9 | 25;17 | FREE TEXT | 
  | 
| 284.9 | UDF10 | 25;18 | FREE TEXT | 
  | 
| 285 | TEXT-STAGING | 22.1;0 | WORD-PROCESSING #165.5285 | 
  | 
| 286 | TEXT-SITE SPECIFIC DATA ITEMS | 22.2;0 | WORD-PROCESSING #165.5286 | 
  | 
| 287 | TEXT-COVID-19 | 22.3;0 | WORD-PROCESSING #165.5287 | 
  | 
| 288 | TOBACCO USE SMOKING STATUS | 25;21 | SET | 
 
  | 
| 289 | TEXT-HIV, SCA, DRUG & ETOH | 22.4;0 | WORD-PROCESSING #165.5289 | 
  | 
| 300 | PATIENT REFERRED FOR TREATMENT | BLA1;1 | SET | 
 
  | 
| 301 | LENGTH OF STAY | BLA1;2 | NUMBER | 
  | 
| 302 | HISTORY OF CERVIX CA (PT) | BLA1;3 | SET | 
 
  | 
| 303 | HISTORY OF COLON CA (PT) | BLA1;4 | SET | 
 
  | 
| 304 | HISTORY OF BLADDER CA (PT) | BLA1;5 | SET | 
 
  | 
| 305 | HISTORY OF HEAD & NECK CA (PT) | BLA1;6 | SET | 
 
  | 
| 306 | HISTORY OF KIDNEY CA (PT) | BLA1;7 | SET | 
 
  | 
| 307 | HISTORY OF PROSTATE CA (PT) | BLA1;8 | SET | 
 
  | 
| 308 | HISTORY OF OTHER CA (PT) | BLA1;9 | SET | 
 
  | 
| 309 | HISTORY OF BLADDER CA (FAM) | BLA1;10 | SET | 
 
  | 
| 310 | HISTORY OF COLON CA (FAM) | BLA1;11 | SET | 
 
  | 
| 311 | HISTORY OF LUNG CA (FAM) | BLA1;12 | SET | 
 
  | 
| 312 | HISTORY OF PROSTATE CA (FAM) | BLA1;13 | SET | 
 
  | 
| 313 | HISTORY OF OTHER CA (FAM) | BLA1;14 | SET | 
 
  | 
| 314 | SMOKING HISTORY | BLA1;15 | NUMBER | 
  | 
| 315 | DURATION OF SMOKING HISTORY | BLA1;16 | NUMBER | 
  | 
| 316 | DURATION OF SMOKE FREE HISTORY | BLA1;17 | NUMBER | 
  | 
| 317 | GROSS HEMATURIA | BLA1;18 | SET | 
 
  | 
| 318 | MICROSCOPIC HEMATURIA | BLA1;19 | SET | 
 
  | 
| 319 | URINARY FREQUENCY | BLA1;20 | SET | 
 
  | 
| 320 | BLADDER IRRITABILITY | BLA1;21 | SET | 
 
  | 
| 321 | DYSURIA | BLA1;22 | SET | 
 
  | 
| 322 | OTHER CLINICAL DETECTIONS | BLA1;23 | SET | 
 
  | 
| 323 | ONSET OF SYMPTOMS | BLA1;24 | DATE | 
  | 
| 324 | DURATION OF GROSS HEMATURIA | BLA1;25 | NUMBER | 
  | 
| 325 | DURATION OF DYSURIA | BLA1;26 | NUMBER | 
  | 
| 326 | BIMANAUL EXAM OF BLADDER | BLA1;27 | SET | 
 
  | 
| 327 | CYSTOSCOPY WITH BIOPSY | BLA1;28 | SET | 
 
  | 
| 328 | CYSTOSCOPY WITHOUT BIOPSY | BLA1;29 | SET | 
 
  | 
| 329 | FLOW CYTOMETRY | BLA1;30 | SET | 
 
  | 
| 330 | INTRAVENOUS PYELOGRAM (BLA) | BLA1;31 | SET | 
 
  | 
| 331 | URINE CYTOLOGY | BLA1;32 | SET | 
 
  | 
| 332 | URINALYSIS | BLA1;33 | SET | 
 
  | 
| 333 | OTHER DIAGNOSTIC PROCEDURES | BLA1;34 | SET | 
 
  | 
| 334 | SPECIALTY MAKING DIAGNOSIS | BLA1;35 | SET | 
 
  | 
| 335 | ABDOMINAL ULTRASOUND | BLA1;36 | SET | 
 
  | 
| 336 | BONE IMAGING | BLA1;37 | SET | 
 
  | 
| 337 | CHEST X-RAY (BLADDER) | BLA1;38 | SET | 
 
  | 
| 338 | CT CHEST/LUNG | BLA1;39 | SET | 
 
  | 
| 339 | CT ABDOMEN/PELVIS | BLA1;40 | SET | 
 
  | 
| 340 | CT OTHER | BLA1;41 | SET | 
 
  | 
| 341 | MRI PELVIS/ABDOMEN | BLA1;42 | SET | 
 
  | 
| 342 | MRI OTHER | BLA1;43 | SET | 
 
  | 
| 343 | OTHER STAGING PROCEDURES | BLA1;44 | SET | 
 
  | 
| 344 | PRESENCE OF HYDRONEPHROSIS | BLA1;45 | SET | 
 
  | 
| 345 | PRESENCE OF MULTIPLE TUMORS | BLA1;46 | SET | 
 
  | 
| 346 | PROTOCOL ELIGIBILITY STATUS | BLA2;1 | SET | 
 
  | 
| 347 | MANAGING PHYSICIAN (PRIMARY) | BLA2;2 | POINTER TO BLADDER PHYSICIAN SPECIALTY FILE (#166.12) | BLADDER PHYSICIAN SPECIALTY(#166.12)
  | 
| 348 | MANAGING PHYSICIAN (SECONDARY) | BLA2;3 | POINTER TO BLADDER PHYSICIAN SPECIALTY FILE (#166.12) | BLADDER PHYSICIAN SPECIALTY(#166.12)
  | 
| 349 | TUMOR RESECTION DURING TURB | BLA2;4 | SET | 
 
  | 
| 350 | TYPE OF URINARY DIVERSION | BLA2;5 | SET | 
 
  | 
| 351 | PELVIC LYMPH NODE DISSECT (BL) | BLA2;6 | SET | 
 
  | 
| 352 | BLEEDING REQUIRING TRANSFUSION | BLA2;7 | SET | 
 
  | 
| 353 | DEEP VENOUS THROMBOSIS | BLA2;8 | SET | 
 
  | 
| 354 | MYOCARDIAL INFARCTION (MI) | BLA2;9 | SET | 
 
  | 
| 355 | PELVIC ABSCESS | BLA2;10 | SET | 
 
  | 
| 356 | PNEUMONIA REQ ANTIBIOTICS | BLA2;11 | SET | 
 
  | 
| 357 | POST-OPERATIVE DEATH | BLA2;12 | SET | 
 
  | 
| 358 | PULMONARY EMBOLISM/THROMBOSIS | BLA2;13 | SET | 
 
  | 
| 359 | REOPERATION | BLA2;14 | SET | 
 
  | 
| 360 | OTHER SURGICAL COMPLICATIONS | BLA2;15 | SET | 
 
  | 
| 361 | DATE RADIATION ENDED | BLA2;16 | DATE | 
  | 
| 362 | TOTAL RAD (cGy/rad) DOSE | BLA2;17 | NUMBER | 
  | 
| 363 | REGIONAL TREATMENT MODALITY | BLA2;18 | POINTER TO REGIONAL TREATMENT MODALITY FILE (#166.13) | REGIONAL TREATMENT MODALITY(#166.13)
  | 
| 363.1 | BOOST TREATMENT MODALITY | 24;9 | POINTER TO REGIONAL TREATMENT MODALITY FILE (#166.13) | REGIONAL TREATMENT MODALITY(#166.13)
  | 
| 364 | URINARY INCONTINENCE | BLA2;19 | SET | 
 
  | 
| 365 | HEMATURIA | BLA2;20 | SET | 
 
  | 
| 366 | RADIATION BOWEL INJURY | BLA2;21 | SET | 
 
  | 
| 367 | DATE CHEMOTHERAPY ENDED | BLA2;22 | DATE | 
  | 
| 368 | ROUTE CHEMOTHERAPY ADMIN | BLA2;23 | SET | 
 
  | 
| 369 | ADRIAMYCIN | BLA2;24 | SET | 
 
  | 
| 370 | CARBOPLATINUM | BLA2;25 | SET | 
 
  | 
| 371 | CISPLATIN | BLA2;26 | SET | 
 
  | 
| 372 | CYCLOPHOSPHAMIDE | BLA2;27 | SET | 
 
  | 
| 373 | 5-FLUOROURACIL | BLA2;28 | SET | 
 
  | 
| 374 | GALLIUM NITRATE | BLA2;29 | SET | 
 
  | 
| 375 | IFOSFAMIDE | BLA2;30 | SET | 
 
  | 
| 376 | METHOTREXATE | BLA2;31 | SET | 
 
  | 
| 377 | TAXOL | BLA2;32 | SET | 
 
  | 
| 378 | THIOTEPA | BLA2;33 | SET | 
 
  | 
| 379 | VINBLASTINE | BLA2;34 | SET | 
 
  | 
| 380 | OTHER CHEMOTHERAPEUTIC AGENTS | BLA2;35 | SET | 
 
  | 
| 381 | INDICATION FOR ADMIN OF AGENTS | BLA2;36 | SET | 
 
  | 
| 382 | REASON CHEMOTHERAPY STOPPED | BLA2;41 | SET | 
 
  | 
| 383 | BCG | BLA2;37 | SET | 
 
  | 
| 384 | INTERFERON | BLA2;38 | SET | 
 
  | 
| 385 | INTERLEUKIN-2 | BLA2;39 | SET | 
 
  | 
| 386 | OTHER TYPE OF IMMUNOTHERAPY | BLA2;40 | SET | 
 
  | 
| 387 | TYPE OF 1ST RECURRENCE/BLADDER | BLA2;42 | SET | 
 
  | 
| 400 | HISTORY OF THYROID CA (FAM) | THY1;1 | SET | 
 
  | 
| 401 | HISTORY OF LYMPHOMA (PT) | THY1;2 | SET | 
 
  | 
| 402 | HISTORY OF CHILDHOOD MALIG | THY1;3 | SET | 
 
  | 
| 403 | PRIOR EXPOSURE TO RADIATION | THY1;4 | SET | 
 
  | 
| 404 | HISTORY OF GOITER (PT) | THY1;5 | SET | 
 
  | 
| 405 | HISTORY OF GOITER (FAM) | THY1;6 | SET | 
 
  | 
| 406 | HISTORY OF GRAVES DISEASE (PT) | THY1;7 | SET | 
 
  | 
| 407 | HISTORY OF THYROIDITIS (PT) | THY1;8 | SET | 
 
  | 
| 408 | DYSPHAGIA | THY1;9 | SET | 
 
  | 
| 409 | HOARSENESS OR VOICE CHANGE | THY1;10 | SET | 
 
  | 
| 410 | NECK NODAL MASS | THY1;11 | SET | 
 
  | 
| 411 | PAIN, BONE | THY1;12 | SET | 
 
  | 
| 412 | PAIN, NECK | THY1;13 | SET | 
 
  | 
| 413 | PATHOLOGIC FRACTURE | THY1;14 | SET | 
 
  | 
| 414 | STRIDOR/DIFFICULTY BREATHING | THY1;15 | SET | 
 
  | 
| 415 | THYROID MASS | THY1;16 | SET | 
 
  | 
| 416 | WEIGHT LOSS | THY1;17 | SET | 
 
  | 
| 417 | OTHER SIGNS/SYMPTOMS | THY1;18 | SET | 
 
  | 
| 418 | BONE SCAN (THYROID) | THY1;19 | SET | 
 
  | 
| 419 | CHEST X-RAY (THYROID) | THY1;20 | SET | 
 
  | 
| 420 | CT SCAN OF NECK (THYROID) | THY1;21 | SET | 
 
  | 
| 421 | CT SCAN OF CHEST | THY1;22 | SET | 
 
  | 
| 422 | INCISIONAL BIOPSY OF THYROID | THY1;23 | SET | 
 
  | 
| 423 | LARYNGOSCOPY | THY1;24 | SET | 
 
  | 
| 424 | NECK X-RAY (AP & LATERAL) | THY1;25 | SET | 
 
  | 
| 425 | NEEDLE ASPIRATION OF NECK NODE | THY1;26 | SET | 
 
  | 
| 426 | NEEDLE ASPIRATION OF THYROID | THY1;27 | SET | 
 
  | 
| 427 | MRI OF NECK | THY1;28 | SET | 
 
  | 
| 428 | THYROID SCAN | THY1;29 | SET | 
 
  | 
| 429 | ULTRASOUND OF THYROID | THY1;30 | SET | 
 
  | 
| 430 | OTHER DIAGNOSTIC/SURGICAL TEST | THY1;31 | SET | 
 
  | 
| 431 | BLOOD VESSEL INVASION | THY1;32 | SET | 
 
  | 
| 432 | EXTRA-THYROIDAL EXTENSION | THY1;33 | SET | 
 
  | 
| 433 | MULTIFOCAL | THY1;34 | SET | 
 
  | 
| 434 | LOCATION OF POSITIVE NODES | THY1;35 | SET | 
 
  | 
| 435 | DATE MOST DEFINITIVE SURG DIS | THY1;36 | DATE | 
  | 
| 436 | AIRWAY PROBLEM | THY1;37 | SET | 
 
  | 
| 437 | BLEEDING/HEMATOMA | THY1;38 | SET | 
 
  | 
| 438 | HYPOCALCEMIA | THY1;39 | SET | 
 
  | 
| 439 | RECURRENT NERVE INJURY | THY1;40 | SET | 
 
  | 
| 440 | WOUND INFECTION | THY1;41 | SET | 
 
  | 
| 441 | POSTOPERATIVE DEATH | THY1;42 | SET | 
 
  | 
| 442 | REGIONAL DOSE: cGy | THY1;43 | NUMBER | 
  | 
| 443 | BOOST DOSE: cGy | THY1;44 | NUMBER | 
  | 
| 444 | INITIAL DOSE OF RADIOIODINE | THY1;45 | NUMBER | 
  | 
| 445 | SECOND DOSE OF RADIOIODINE | THY1;46 | NUMBER | 
  | 
| 446 | ADJUVANT CHEMOTHERAPY (THY) | THY1;47 | SET | 
 
  | 
| 500 | HISTORY OF SOFT TIS SARC (FAM) | STS1;1 | SET | 
 
  | 
| 501 | HISTORY OF ANY CANCER (PT) | STS1;2 | SET | 
 
  | 
| 502 | ANGIOGRAM OF PRIMARY | STS1;3 | SET | 
 
  | 
| 503 | BONE MARROW ASPIRATE OR BIOPSY | STS1;4 | SET | 
 
  | 
| 504 | BONE SCAN (SOFT TIS SARCOMA) | STS1;5 | SET | 
 
  | 
| 505 | CHEST X-RAY (STS/NHL) | STS1;6 | SET | 
 
  | 
| 506 | CT SCAN OF CHEST (STS) | STS1;7 | SET | 
 
  | 
| 507 | CT SCAN OF PRIMARY | STS1;8 | SET | 
 
  | 
| 508 | LIVER FUNCTION STUDIES (STS) | STS1;9 | SET | 
 
  | 
| 509 | LYMPHANGIOGRAM | STS1;10 | SET | 
 
  | 
| 510 | MRI OF PRIMARY | STS1;11 | SET | 
 
  | 
| 511 | MRI OF OTHER | STS1;12 | SET | 
 
  | 
| 512 | SKELETAL X-RAY | STS1;13 | SET | 
 
  | 
| 513 | SONOGRAM | STS1;14 | SET | 
 
  | 
| 514 | CYTOGENETICS | STS1;15 | SET | 
 
  | 
| 515 | ELECTRON MICROSCOPY | STS1;16 | SET | 
 
  | 
| 516 | IMMUNOHISTOCHEMISTRY | STS1;17 | SET | 
 
  | 
| 517 | IN SITU HYBRIDIZATION | STS1;18 | SET | 
 
  | 
| 518 | OUTSIDE CONFIRMATION REQUESTED | STS1;19 | SET | 
 
  | 
| 519 | SUBSITE | STS1;20 | POINTER TO ONCOLOGY SUBSITE FILE (#166.3) | ONCOLOGY SUBSITE(#166.3)
  | 
| 520 | TYPE OF ADDITIONAL CODING SYS | STS1;21 | SET | 
 
  | 
| 521 | VALUE OF ADDITIONAL CODING SYS | STS1;22 | SET | 
 
  | 
| 522 | PATHOLOGIC SIZE OF TUMOR | STS1;23 | NUMBER | 
  | 
| 523 | DEPTH OF TUMOR | STS1;24 | SET | 
 
  | 
| 524 | CONSULTATIONS (MED ONCOLOGIST) | STS1;25 | SET | 
 
  | 
| 525 | CONSULTATIONS (RAD ONCOLOGIST) | STS1;26 | SET | 
 
  | 
| 526 | TREATING SURGEON | STS2;1 | SET | 
 
  | 
| 527 | ASA CLASS | STS2;2 | SET | 
 
  | 
| 528 | FINE NEEDLE ASPIRATION | STS1;27 | NUMBER | 
  | 
| 529 | CORE NEEDLE BIOPSY | STS1;28 | NUMBER | 
  | 
| 530 | INCISIONAL BIOPSY (STS PCE) | STS1;29 | NUMBER | 
  | 
| 531 | EXCISIONAL BIOPSY | STS1;30 | NUMBER | 
  | 
| 532 | EXTERNAL BEAM RADIATION | STS2;3 | SET | 
 
  | 
| 533 | EXTERNAL BEAM RAD FRACTIONS | STS2;4 | NUMBER | 
  | 
| 534 | EXTERNAL BEAM RADIATION ENERGY | STS2;5 | NUMBER | 
  | 
| 535 | INTRAOPERATIVE RADIATION | STS2;6 | SET | 
 
  | 
| 536 | INTRAOPERATIVE RADIATION DOSE | STS2;7 | NUMBER | 
  | 
| 537 | INTRAOPERATIVE RADIATION ENER | STS2;8 | NUMBER | 
  | 
| 538 | BRACHYTHERAPY | STS2;9 | SET | 
 
  | 
| 539 | BRACHYTHERAPY DAYS | STS2;10 | NUMBER | 
  | 
| 540 | BRACHYTHERAPY RADIATION DOSE | STS2;11 | NUMBER | 
  | 
| 541 | DATE BRACHYTHERAPY STARTED | STS2;12 | DATE | 
  | 
| 542 | DATE BRACHYTHERAPY ENDED | STS2;13 | DATE | 
  | 
| 543 | CYTOXAN | STS2;14 | SET | 
 
  | 
| 544 | DTIC | STS2;15 | SET | 
 
  | 
| 545 | DOXORUBICIN (STS) | STS2;16 | SET | 
 
  | 
| 546 | ETOPOSIDE | STS2;17 | SET | 
 
  | 
| 547 | CISPLATIN METHOD OF DELIVERY | STS2;18 | SET | 
 
  | 
| 548 | CYTOXAN METHOD OF DELIVERY | STS2;19 | SET | 
 
  | 
| 549 | DTIC METHOD OF DELIVERY | STS2;20 | SET | 
 
  | 
| 550 | DOXORUBICIN METHOD OF DELIVERY | STS2;21 | SET | 
 
  | 
| 551 | ETOPOSIDE METHOD OF DELIVERY | STS2;22 | SET | 
 
  | 
| 552 | IFOSFAMIDE METHOD OF DELIVERY | STS2;23 | SET | 
 
  | 
| 553 | CISPLATIN LOCATION | STS2;24 | SET | 
 
  | 
| 554 | CYTOXAN LOCATION | STS2;25 | SET | 
 
  | 
| 555 | DTIC LOCATION | STS2;26 | SET | 
 
  | 
| 556 | DOXORUBICIN LOCATION | STS2;27 | SET | 
 
  | 
| 557 | ETOPOSIDE LOCATION | STS2;28 | SET | 
 
  | 
| 558 | IFOSFAMIDE LOCATION | STS2;29 | SET | 
 
  | 
| 559 | COLONY STIMULATING FACTORS | STS2;30 | SET | 
 
  | 
| 560 | PROTOCOL PARTICIPATION | STS2;31 | SET | 
 
  | 
| 561 | OTHER PROTOCOL | STS2;32 | SET | 
 
  | 
| 562 | REFERRED TO REHAB SERVICES | STS2;33 | SET | 
 
  | 
| 563 | PHYSICAL THERAPY/REHABILTATION | STS2;34 | SET | 
 
  | 
| 564 | TRANSFERRED TO REHABILITATION | STS2;35 | SET | 
 
  | 
| 565 | NUMBER OF HOSPITALIZATIONS | STS2;36 | NUMBER | 
  | 
| 566 | TOTAL LENGTH OF STAYS | STS2;37 | NUMBER | 
  | 
| 567 | DATE EXT BEAM RAD STARTED | STS2;38 | DATE | 
  | 
| 600 | CLINICAL DX WITH BONE LESION | PRO1;1 | SET | 
 
  | 
| 601 | CLINICAL DX BY RECTAL EXAM | PRO1;2 | SET | 
 
  | 
| 602 | CYTOLOGY | PRO1;3 | SET | 
 
  | 
| 603 | INCIDENTAL FINDING IN TURP | PRO1;4 | SET | 
 
  | 
| 604 | NEEDLE ASPIRATION BIOPSY | PRO1;5 | SET | 
 
  | 
| 605 | NEEDLE BIOPSY, NOS | PRO1;6 | SET | 
 
  | 
| 606 | PERINEAL BIOPSY | PRO1;7 | SET | 
 
  | 
| 607 | TRANSRECTAL BIOPSY | PRO1;8 | SET | 
 
  | 
| 608 | TRUS | PRO1;9 | SET | 
 
  | 
| 609 | TRANSURETHRAL RESECTION | PRO1;10 | SET | 
 
  | 
| 610 | OTHER METHOD OF DX (PROSTATE) | PRO1;11 | SET | 
 
  | 
| 611 | BONE MARROW ASPIRATION | PRO1;12 | SET | 
 
  | 
| 612 | BONE SCAN (PROSTATE) | PRO1;13 | SET | 
 
  | 
| 613 | BONE X-RAY | PRO1;14 | SET | 
 
  | 
| 614 | CHEST X-RAY (PROSTATE) | PRO1;15 | SET | 
 
  | 
| 615 | CT SCAN OF PRIMARY SITE | PRO1;16 | SET | 
 
  | 
| 616 | INTRAVENOUS PYELOGRAM (PRO) | PRO1;17 | SET | 
 
  | 
| 617 | LIVER SCAN | PRO1;18 | SET | 
 
  | 
| 618 | MRI (PRO) | PRO1;19 | SET | 
 
  | 
| 619 | PELVIC LYMPH NODE DISSECT (PR) | PRO1;20 | SET | 
 
  | 
| 620 | PROSTATIC ACID PHOSPHATASE | PRO1;21 | SET | 
 
  | 
| 621 | PROSTATE SPECIFIC ANTIGEN | PRO1;22 | SET | 
 
  | 
| 622 | OTHER DIAGNOSTIC INFORMATION | PRO1;23 | SET | 
 
  | 
| 623 | GLEASON SCORE CLIN - OBSOLETE | PRO1;24 | FREE TEXT | 
  | 
| 623.1 | PREDOMINANT PATTERN (02-40) | PRO2;43 | NUMBER | 
  | 
| 623.2 | LESSER PATTERN (02-40) | PRO2;44 | NUMBER | 
  | 
| 623.3 | GLEASON'S SCORE (50-70) | PRO2;45 | FREE TEXT | 
  | 
| 623.4 | PREDOMINANT PATTERN (50-70) | PRO2;46 | NUMBER | 
  | 
| 623.5 | LESSER PATTERN (50-70) | PRO2;47 | NUMBER | 
  | 
| 624 | RESEARCH PROTOCOL | PRO1;25 | SET | 
 
  | 
| 625 | RAD THERAPY PLANNED/GIVEN | PRO1;26 | SET | 
 
  | 
| 626 | INTERSTITIAL RAD PLANNED/GIVEN | PRO1;27 | SET | 
 
  | 
| 627 | IODINE 125 | PRO1;28 | SET | 
 
  | 
| 628 | GOLD 198 | PRO1;29 | SET | 
 
  | 
| 629 | PALLADIUM 103 | PRO1;30 | SET | 
 
  | 
| 630 | IRIDIUM 192 | PRO1;31 | SET | 
 
  | 
| 631 | OTHER INTERSTITIAL, NOS | PRO1;32 | SET | 
 
  | 
| 632 | EXTERNAL RAD PLANNED/GIVEN | PRO1;33 | SET | 
 
  | 
| 633 | PROSTATE REGION ONLY | PRO1;34 | SET | 
 
  | 
| 634 | PROSTATE AND PELVIC NODES | PRO1;35 | SET | 
 
  | 
| 635 | PROSTATE & PELVIC PARA-AORTIC | PRO1;36 | SET | 
 
  | 
| 636 | DISTANT METASTATIC SITES | PRO1;37 | SET | 
 
  | 
| 637 | OTHER EXTERNAL SITES, NOS | PRO1;38 | SET | 
 
  | 
| 638 | TOTAL RAD DOSE (PROSTATE) | PRO1;39 | SET | 
 
  | 
| 639 | TOTAL RAD DOSE (PELVIC NODES) | PRO1;40 | SET | 
 
  | 
| 640 | TOTAL RAD DOSE (PARA-AORTIC) | PRO1;41 | SET | 
 
  | 
| 641 | RESEARCH PROTOCOL (RADIATION) | PRO1;42 | SET | 
 
  | 
| 642 | HORMONE THERAPY PLANNED/GIVEN | PRO1;43 | SET | 
 
  | 
| 643 | ESTROGENS | PRO1;44 | SET | 
 
  | 
| 644 | ANTIANDROGENS | PRO1;45 | SET | 
 
  | 
| 645 | PROGESTATIONAL AGENTS | PRO1;46 | SET | 
 
  | 
| 646 | LUTEINIZING HORMONES | PRO1;47 | SET | 
 
  | 
| 647 | ORCHIECTOMY | PRO1;48 | SET | 
 
  | 
| 648 | OTHER EXOGENOUS HORMONE AGENTS | PRO1;49 | SET | 
 
  | 
| 649 | BACKACHE (1ST RECURRENCE) | PRO1;50 | SET | 
 
  | 
| 650 | BONE SCAN (1ST RECURRENCE) | PRO1;51 | SET | 
 
  | 
| 651 | LETHARGY | PRO1;52 | SET | 
 
  | 
| 652 | RECTAL EXAM (1ST RECURRENCE) | PRO1;53 | SET | 
 
  | 
| 653 | TUMOR MARKER (1ST RECURRENCE) | PRO1;54 | SET | 
 
  | 
| 654 | WEIGHT LOSS (1ST RECURRENCE) | PRO1;55 | SET | 
 
  | 
| 655 | OTHER METHODS (1ST RECURRENCE) | PRO1;56 | SET | 
 
  | 
| 656 | REASON FOR 2ND COURSE | PRO1;57 | SET | 
 
  | 
| 657 | FAM HIST OF PROSTATE CA (PR98) | PRO2;1 | SET | 
 
  | 
| 658 | HEMATURIA (PR98) | PRO2;2 | SET | 
 
  | 
| 659 | LOWER BACK PAIN (PR98) | PRO2;3 | SET | 
 
  | 
| 660 | TROUBLE URINATING (PR98) | PRO2;4 | SET | 
 
  | 
| 661 | CLIN DX W/ BONE LESION (PR98) | PRO2;5 | SET | 
 
  | 
| 662 | CLIN DX BY RECTAL EXAM (PR98) | PRO2;6 | SET | 
 
  | 
| 663 | CYTOLOGY (PR98) | PRO2;7 | SET | 
 
  | 
| 664 | DIGITAL TRANSRECTAL BIO (PR98) | PRO2;8 | SET | 
 
  | 
| 665 | INCIDENTAL FIND IN TURP (PR98) | PRO2;9 | SET | 
 
  | 
| 666 | NEEDLE BIOPSY, NOS (PR98) | PRO2;10 | SET | 
 
  | 
| 667 | PERINEAL BIOPSY (PR98) | PRO2;11 | SET | 
 
  | 
| 668 | PSA METHOD OF DIAGNOSIS (PR98) | PRO2;12 | SET | 
 
  | 
| 669 | TRANSRECTAL BIOPSY (PR98) | PRO2;13 | SET | 
 
  | 
| 670 | TRANSURETHRAL RESECTION (PR98) | PRO2;14 | SET | 
 
  | 
| 671 | BONE MARROW ASPIRATION (PR98) | PRO2;15 | SET | 
 
  | 
| 672 | BONE SCAN (PR98) | PRO2;16 | SET | 
 
  | 
| 673 | BONE X-RAY (PR98) | PRO2;17 | SET | 
 
  | 
| 674 | CHEST X-RAY (PR98) | PRO2;18 | SET | 
 
  | 
| 675 | CT SCAN OF ABDOMEN (PR98) | PRO2;19 | SET | 
 
  | 
| 676 | CT SCAN OF PELVIS (PR98) | PRO2;20 | SET | 
 
  | 
| 677 | INTRAVENOUS PYELOGRAM (PR98) | PRO2;21 | SET | 
 
  | 
| 678 | MRI (PR98) | PRO2;22 | SET | 
 
  | 
| 679 | PELVIC LYMPH ND DISSECT (PR98) | PRO2;23 | SET | 
 
  | 
| 680 | POLYMERASE CHAIN REACT (PR98) | PRO2;24 | SET | 
 
  | 
| 681 | PROSTATIC ACID PHOSPH (PR98) | PRO2;25 | SET | 
 
  | 
| 682 | PSA DIAGNOSTIC EVAL (PR98) | PRO2;26 | SET | 
 
  | 
| 683 | ULTRASOUND OF ABDOMEN (PR98) | PRO2;27 | SET | 
 
  | 
| 684 | PSA | PRO2;28 | FREE TEXT | 
  | 
| 685 | WATCHFUL WAITING (PR98) | PRO2;29 | SET | 
 
  | 
| 686 | LENGTH OF STAY (PR98) | PRO2;30 | NUMBER | 
  | 
| 687 | LAPAROSCOPIC (PR98) | PRO2;31 | SET | 
 
  | 
| 688 | OPEN (PR98) | PRO2;32 | SET | 
 
  | 
| 689 | PERMANENT RECTAL INJURY (PR98) | PRO2;33 | SET | 
 
  | 
| 690 | THROMBOEMBOLISM (PR98) | PRO2;34 | SET | 
 
  | 
| 691 | URETHRAL STRICTURE (PR98) | PRO2;35 | SET | 
 
  | 
| 692 | RADIATION FACILITY | PRO2;36 | SET | 
 
  | 
| 693 | ROUTE OF INTERSTITIAL RAD | PRO2;37 | SET | 
 
  | 
| 694 | TYPE OF RADIATION ADMIN | PRO2;38 | SET | 
 
  | 
| 695 | GASTROINTESTINAL COMPLICATIONS | PRO2;39 | SET | 
 
  | 
| 696 | GASTROURINARY COMPLICATIONS | PRO2;40 | SET | 
 
  | 
| 697 | ANORECTAL COMPLICATIONS | PRO2;41 | SET | 
 
  | 
| 698 | CHRONIC COMPLICATIONS | PRO2;42 | SET | 
 
  | 
| 699 | URETHRAL/BLADDER COMPLICATIONS | PRO2;48 | SET | 
 
  | 
| 699.1 | DATE OF ORCHIECTOMY | PRO2;49 | DATE | 
  | 
| 700 | HISTORY OF COLORECTAL CA (FAM) | COL1;1 | SET | 
 
  | 
| 701 | HISTORY OF COLORECTAL CA (PT) | COL1;2 | SET | 
 
  | 
| 702 | MULTIPLE COLORECTAL PRIMARIES | COL1;3 | SET | 
 
  | 
| 703 | HISTORY OF BREAST CA (PT) | COL1;4 | SET | 
 
  | 
| 704 | HISTORY OF LUNG CA (PT) | COL1;5 | SET | 
 
  | 
| 705 | HISTORY OF OVARIAN CA (PT) | COL1;6 | SET | 
 
  | 
| 706 | HISTORY OF OVARIAN CARCINOMA | COL1;7 | SET | 
 
  | 
| 707 | HISTORY OF STOMACH CA (PT) | COL1;8 | SET | 
 
  | 
| 708 | HISTORY OF THYROID CA (PT) | COL1;9 | SET | 
 
  | 
| 709 | HISTORY OF UTERUS CA (PT) | COL1;10 | SET | 
 
  | 
| 710 | PREVIOUS TAH/BSO | COL1;11 | SET | 
 
  | 
| 711 | FAMILIAL ADENOMATOUS POLYPS | COL1;12 | SET | 
 
  | 
| 712 | HNPCC | COL1;13 | SET | 
 
  | 
| 713 | INFLAMMATORY BOWEL DISEASE | COL1;14 | SET | 
 
  | 
| 714 | PRIOR POLYPS | COL1;15 | SET | 
 
  | 
| 715 | POLYPS | COL1;16 | NUMBER | 
  | 
| 716 | DURATION OF ANEMIA | COL1;17 | NUMBER | 
  | 
| 717 | DURATION OF BOWEL OBSTRUCTION | COL1;18 | NUMBER | 
  | 
| 718 | DURATION OF BOWEL HABIT CHANGE | COL1;19 | NUMBER | 
  | 
| 719 | DURATION OF EMERGENCY PRES-OBS | COL1;20 | NUMBER | 
  | 
| 720 | DURATION OF JAUNDICE | COL1;21 | NUMBER | 
  | 
| 721 | DURATION OF MALAISE | COL1;22 | NUMBER | 
  | 
| 722 | DURATION OF BLOOD IN STOOL | COL1;23 | NUMBER | 
  | 
| 723 | DURATION OF PAIN (ABDOMINAL) | COL1;24 | NUMBER | 
  | 
| 724 | DURATION OF PAIN (PELVIC) | COL1;25 | NUMBER | 
  | 
| 725 | DURATION OF RECTAL BLEEDING | COL1;26 | NUMBER | 
  | 
| 726 | DURATION OF OTHER | COL1;27 | NUMBER | 
  | 
| 727 | ENDOSCOPIC METHOD | COL1;28 | SET | 
 
  | 
| 728 | RADIOGRAPHIC METHOD | COL1;29 | SET | 
 
  | 
| 729 | SCREENING DIGITAL RECTAL EXAM | COL1;30 | SET | 
 
  | 
| 730 | SCREENING PHYSICAL EXAM METHOD | COL1;31 | SET | 
 
  | 
| 731 | OTHER INITIAL METHOD | COL1;32 | SET | 
 
  | 
| 732 | REASON LEADING TO EVENTUAL DX | COL1;33 | SET | 
 
  | 
| 733 | BARIUM ENEMA, DOUBLE CONTRAST | COL1;34 | SET | 
 
  | 
| 734 | BARIUM ENEMA, SINGLE CONTRAST | COL1;35 | SET | 
 
  | 
| 735 | BARIUM ENEMA, NOS | COL1;36 | SET | 
 
  | 
| 736 | BIOPSY OF PRIMARY SITE | COL1;37 | SET | 
 
  | 
| 737 | BIOPSY OF METASTATIC SITE | COL1;38 | SET | 
 
  | 
| 738 | CT SCAN OF LIVER | COL1;39 | SET | 
 
  | 
| 739 | CT SCAN OF PRIMARY SITE (COL) | COL1;40 | SET | 
 
  | 
| 740 | CARCINOEMBRYONIC ANTIGEN (CEA) | COL1;41 | SET | 
 
  | 
| 741 | CHEST ROENTGENOGRAM | COL1;42 | SET | 
 
  | 
| 742 | COLONOSCOPY | COL1;43 | SET | 
 
  | 
| 743 | DIGITAL RECTAL EXAM | COL1;44 | SET | 
 
  | 
| 744 | FLEXIBLE SIGMOIDOSCOPY | COL1;45 | SET | 
 
  | 
| 745 | INTRAVENOUS PYELOGRAM (COL) | COL1;46 | SET | 
 
  | 
| 746 | SERUM-LIVER FUNCTION TEST | COL1;47 | SET | 
 
  | 
| 747 | MRI (COL) | COL1;48 | SET | 
 
  | 
| 748 | PROCTOSCOPY (RIGID) | COL1;49 | SET | 
 
  | 
| 749 | STOOL GUAIAC (OCCULT BLOOD) | COL1;50 | SET | 
 
  | 
| 750 | ULTRASOUND, LIVER, ABDOMEN | COL1;51 | SET | 
 
  | 
| 751 | ULTRASOUND, ENDORECTAL | COL1;52 | SET | 
 
  | 
| 752 | TUMOR LEVEL-ENDOSCOPIC EXAM | COL2;1 | NUMBER | 
  | 
| 753 | LEVEL OF RECTAL TUMOR | COL2;2 | SET | 
 
  | 
| 754 | PROXIMAL MARGIN OF RESECTION | COL2;3 | SET | 
 
  | 
| 755 | DISTAL MARGIN OF RESECTION | COL2;4 | SET | 
 
  | 
| 756 | RADIAL MARGIN OF RESECTION | COL2;5 | SET | 
 
  | 
| 757 | DIST TO CLOSEST MUCOSAL MARGIN | COL2;6 | NUMBER | 
  | 
| 758 | DIST TO CLOSEST RADIAL MARGIN | COL2;7 | NUMBER | 
  | 
| 759 | BLOOD VESSEL OR LYMPHATIC INV | COL2;8 | SET | 
 
  | 
| 760 | EXTRAMURAL VENOUS INVASION | COL2;9 | SET | 
 
  | 
| 761 | PROMINENT LYMPHOID INFILTRATE | COL2;10 | SET | 
 
  | 
| 762 | PHYS PROVIDING DEF TREATMENT | COL2;11 | SET | 
 
  | 
| 763 | ADDITIONAL SURGICAL PROCEDURES | COL2;12 | NUMBER | 
  | 
| 764 | LAPAROSCOPY USED DURING CDS | COL2;13 | SET | 
 
  | 
| 765 | METHOD OF ANASTOMOSIS | COL2;14 | SET | 
 
  | 
| 766 | CM FROM ANASTOMOSIS TO DENTATE | COL2;15 | NUMBER | 
  | 
| 767 | COLOSTOMY | COL2;16 | SET | 
 
  | 
| 768 | OOPHORECTOMY | COL2;17 | SET | 
 
  | 
| 769 | PATHOLOGICAL STATUS | COL2;18 | SET | 
 
  | 
| 770 | ABDOMINAL INFECTION | COL2;19 | SET | 
 
  | 
| 771 | ABSCESS | COL2;20 | SET | 
 
  | 
| 772 | ADMISSION FOR NEUTROPENIA | COL2;21 | SET | 
 
  | 
| 773 | ANASTOMOTIC DEHISCENCE | COL2;22 | SET | 
 
  | 
| 774 | DEHYDRATION | COL2;23 | SET | 
 
  | 
| 775 | DIARRHEA | COL2;24 | SET | 
 
  | 
| 776 | EARLY BOWEL OBSTRUCTION | COL2;25 | SET | 
 
  | 
| 777 | PERINEAL INFECTION | COL2;26 | SET | 
 
  | 
| 778 | PNEUMONIA (COL) | COL2;27 | SET | 
 
  | 
| 779 | PROCTITIS | COL2;28 | SET | 
 
  | 
| 780 | PULMONARY EMBOLISM (COL) | COL2;29 | SET | 
 
  | 
| 781 | RADIATION ENTERITIS | COL2;30 | SET | 
 
  | 
| 782 | STOMA COMPLICATION | COL2;31 | SET | 
 
  | 
| 783 | URINARY TRACT INFECTION | COL2;32 | SET | 
 
  | 
| 784 | ENDOCAVITARY RADIATION (ECRT) | COL2;33 | SET | 
 
  | 
| 785 | INTRA-OPERATIVE RAD THERAPY | COL2;34 | SET | 
 
  | 
| 786 | PRIMARY TUMOR RAD DOSE (cGy) | COL2;35 | NUMBER | 
  | 
| 787 | NUMBER OF RADIATION TREATMENTS | COL2;36 | NUMBER | 
  | 
| 788 | ADJUVANT CHEMOTHERAPY (COL) | COL2;37 | SET | 
 
  | 
| 789 | 5 FU (FLUOROURACIL) | COL2;38 | SET | 
 
  | 
| 790 | LEUCOVORIN | COL2;39 | SET | 
 
  | 
| 791 | LEVAMISOLE | COL2;40 | SET | 
 
  | 
| 792 | CPT 11 | COL2;41 | SET | 
 
  | 
| 793 | OTHER ADJUVANT THERAPY | COL2;42 | SET | 
 
  | 
| 794 | DURATION OF ADJUVANT THERAPY | COL2;43 | SET | 
 
  | 
| 795 | COMPLETED DURATION OF THERAPY | COL2;44 | SET | 
 
  | 
| 796 | NUTRITIONAL CONSULTATION | COL2;45 | SET | 
 
  | 
| 797 | OCCUPATIONAL THERAPY | COL2;46 | SET | 
 
  | 
| 798 | OSTOMY CONSULTATION | COL2;47 | SET | 
 
  | 
| 799 | PSYCHOSOCIAL | COL2;48 | SET | 
 
  | 
| 800 | HISTORY OF LEUKEMIA (FAM) | NHL1;1 | SET | 
 
  | 
| 801 | HISTORY OF NON-HODGKIN'S LYMPH | NHL1;2 | SET | 
 
  | 
| 802 | HISTORY OF HODGKIN'S LYMPHOMA | NHL1;3 | SET | 
 
  | 
| 803 | 1ST PRIMARY SITE | NHL1;4 | POINTER TO ICDO TOPOGRAPHY FILE (#164) | ICDO TOPOGRAPHY(#164)
  | 
| 804 | 1ST PRIMARY HISTOLOGY | NHL1;5 | POINTER TO ICD-O-2 MORPHOLOGY FILE (#164.1) | ICD-O-2 MORPHOLOGY(#164.1)
  | 
| 805 | 2ND PRIMARY SITE | NHL1;6 | POINTER TO ICDO TOPOGRAPHY FILE (#164) | ICDO TOPOGRAPHY(#164)
  | 
| 806 | 2ND PRIMARY HISTOLOGY | NHL1;7 | POINTER TO ICD-O-2 MORPHOLOGY FILE (#164.1) | ICD-O-2 MORPHOLOGY(#164.1)
  | 
| 807 | ORGAN TRANSPLANT | NHL1;8 | SET | 
 
  | 
| 808 | HIV POSITIVE | NHL1;9 | SET | 
 
  | 
| 809 | CROHN'S DISEASE | NHL1;10 | SET | 
 
  | 
| 810 | HASHIMOTO'S THYROIDITIS | NHL1;11 | SET | 
 
  | 
| 811 | SYSTEMIC LUPUS ERYTHEMATOSUS | NHL1;12 | SET | 
 
  | 
| 812 | RHEUMATOID ARTHRITIS | NHL1;13 | SET | 
 
  | 
| 813 | PNEUMOCYSTIS CARINII | NHL1;14 | SET | 
 
  | 
| 814 | CMV INFECTION | NHL1;15 | SET | 
 
  | 
| 815 | TUBERCULOSIS | NHL1;16 | SET | 
 
  | 
| 816 | MYCOBACTERIUM AVIUM | NHL1;17 | SET | 
 
  | 
| 817 | OTHER PARASITIC INFECTIONS | NHL1;18 | SET | 
 
  | 
| 818 | OTHER CONGENITAL DISEASES | NHL1;19 | SET | 
 
  | 
| 819 | OPPORTUNISTIC DISEASE | NHL1;20 | SET | 
 
  | 
| 820 | PREVIOUS CHEMOTHERAPY | NHL1;21 | SET | 
 
  | 
| 821 | PREVIOUS RADIATION THERAPY | NHL1;22 | SET | 
 
  | 
| 822 | AIDS RISK CATEGORY | NHL1;23 | NUMBER | 
  | 
| 823 | CT SCAN OF BRAIN | NHL1;24 | SET | 
 
  | 
| 824 | CT SCAN OF ABDOMEN/PELVIS | NHL1;25 | SET | 
 
  | 
| 825 | MRI OF BRAIN | NHL1;26 | SET | 
 
  | 
| 826 | MRI OF CHEST | NHL1;27 | SET | 
 
  | 
| 827 | MRI OF ABDOMEN/PELVIS | NHL1;28 | SET | 
 
  | 
| 828 | GALLIUM SCAN | NHL1;29 | SET | 
 
  | 
| 829 | PET SCAN | NHL1;30 | SET | 
 
  | 
| 830 | LUMBAR PUNCTURE | NHL1;31 | SET | 
 
  | 
| 831 | HEMOGLOBIN/HEMATOCRIT | NHL1;32 | SET | 
 
  | 
| 832 | WHITE COUNT | NHL1;33 | SET | 
 
  | 
| 833 | PLATELET COUNT | NHL1;34 | SET | 
 
  | 
| 834 | LACTIC DEHYDROGENASE (LDH) | NHL1;35 | SET | 
 
  | 
| 835 | LIVER FUNCTION STUDIES (NHL) | NHL1;36 | SET | 
 
  | 
| 836 | TOTAL PROTEIN/ALBUMIN | NHL1;37 | SET | 
 
  | 
| 837 | GENE REARRANGEMENTS | NHL1;38 | SET | 
 
  | 
| 838 | REVIEW OF PATHOLOGY/OTHER INST | NHL1;39 | SET | 
 
  | 
| 839 | LYMPH NODE BIOPSY | NHL1;40 | SET | 
 
  | 
| 840 | BONE MARROW BIOPSY | NHL1;41 | SET | 
 
  | 
| 841 | CSF CYTOLOGY | NHL1;42 | SET | 
 
  | 
| 842 | OTHER SITE BIOPSY | NHL1;43 | SET | 
 
  | 
| 843 | SYSTEMIC SYMPTOMS | NHL1;44 | SET | 
 
  | 
| 844 | CD4 COUNT | NHL1;45 | SET | 
 
  | 
| 845 | HIV VIRAL LOADS | NHL1;46 | SET | 
 
  | 
| 846 | SPECIFIC HISTOLOGIC INFO | NHL2;1 | SET | 
 
  | 
| 847 | CELL TYPE OF LYMPHOMA | NHL2;2 | SET | 
 
  | 
| 848 | PATIENT STATUS AT DIAGNOSIS | NHL2;3 | SET | 
 
  | 
| 849 | TYPE OF STAGING SYSTEM (PED) | NHL2;4 | POINTER TO TYPE OF STAGING SYSTEM (PEDIATRIC) FILE (#164.6) | TYPE OF STAGING SYSTEM (PEDIATRIC)(#164.6)
  | 
| 850 | PEDIATRIC STAGE | NHL2;5 | FREE TEXT | 
  | 
| 851 | STAGED BY (PEDIATRIC STAGE) | NHL2;6 | SET | 
 
  | 
| 852 | EXTRANODAL SITE 1 | NHL2;7 | FREE TEXT | 
  | 
| 853 | EXTRANODAL SITE 2 | NHL2;8 | FREE TEXT | 
  | 
| 854 | EXTRANODAL SITE 3 | NHL2;9 | FREE TEXT | 
  | 
| 855 | EXTRANODAL SITE W/C-D SURGERY | NHL2;10 | FREE TEXT | 
  | 
| 856 | EXTRANODAL SITE SURGICAL PROC | NHL2;11 | NUMBER | 
  | 
| 857 | LYMPH NODES ABOVE DIAPHRAGM | NHL2;12 | SET | 
 
  | 
| 858 | LYMPH NODES BELOW DIAPHRAGM | NHL2;13 | SET | 
 
  | 
| 859 | BRAIN | NHL2;14 | SET | 
 
  | 
| 860 | OTHER EXTRANODAL SITE(S) | NHL2;15 | SET | 
 
  | 
| 861 | TOTAL BODY | NHL2;16 | SET | 
 
  | 
| 862 | RADIATION/CHEMO SEQUENCE | NHL2;17 | NUMBER | 
  | 
| 863 | PROTOCOL | NHL2;18 | SET | 
 
  | 
| 864 | SYSTEMIC CHEMOTHERAPY | NHL2;19 | SET | 
 
  | 
| 865 | SYSTEMIC CHEMOTHERAPY DATE | NHL2;20 | DATE | 
  | 
| 866 | SYSTEMIC CHEMOTHERAPY CYCLES | NHL2;21 | NUMBER | 
  | 
| 867 | CHLORAMBUCIL | NHL2;22 | SET | 
 
  | 
| 868 | CYCLOPHOSPHAMIDE (NHL) | NHL2;23 | SET | 
 
  | 
| 869 | DOXORUBICIN (NHL) | NHL2;24 | SET | 
 
  | 
| 870 | FLUDARABINE | NHL2;25 | SET | 
 
  | 
| 871 | CHOP | NHL2;26 | SET | 
 
  | 
| 872 | CVP | NHL2;27 | SET | 
 
  | 
| 873 | COMLA | NHL2;28 | SET | 
 
  | 
| 874 | MACOP-B | NHL2;29 | SET | 
 
  | 
| 875 | M-BACOD | NHL2;30 | SET | 
 
  | 
| 876 | PRO-MACE-Cyta BOM | NHL2;31 | SET | 
 
  | 
| 877 | OTHER SYSTEMIC CHEMO AGENTS | NHL2;32 | SET | 
 
  | 
| 878 | HIGH DOSE SYSTEMIC CHEMO | NHL2;33 | SET | 
 
  | 
| 879 | INTRATHECAL CHEMOTHERAPY | NHL2;34 | SET | 
 
  | 
| 880 | PURPOSE OF INTRATHECAL CHEMO | NHL2;35 | SET | 
 
  | 
| 881 | INTERFERON (NHL) | NHL2;36 | SET | 
 
  | 
| 882 | INTERLEUKIN-2 (IL-2) (NHL) | NHL2;37 | SET | 
 
  | 
| 883 | MONOCLONAL ANTIBODIES | NHL2;38 | SET | 
 
  | 
| 884 | VACCINE THERAPY | NHL2;39 | SET | 
 
  | 
| 900 | DAUGHTER (BR98) | BRE1;1 | SET | 
 
  | 
| 901 | MATERNAL AUNT (BR98) | BRE1;2 | SET | 
 
  | 
| 902 | MATERNAL GRANDMOTHER (BR98) | BRE1;3 | SET | 
 
  | 
| 903 | MOTHER (BR98) | BRE1;4 | SET | 
 
  | 
| 904 | ONE SISTER (BR98) | BRE1;5 | SET | 
 
  | 
| 905 | MORE THAN ONE SISTER (BR98) | BRE1;6 | SET | 
 
  | 
| 906 | FATHER (BR98) | BRE1;7 | SET | 
 
  | 
| 907 | BROTHER (BR98) | BRE1;8 | SET | 
 
  | 
| 908 | FAM HISTORY BREAST CA (BR98) | BRE1;9 | SET | 
 
  | 
| 909 | HISTORY OF BREAST CA (BR98) | BRE1;10 | SET | 
 
  | 
| 910 | SYNCHRONOUS BREAST CA (BR98) | BRE1;11 | SET | 
 
  | 
| 911 | COLON (BR98) | BRE1;12 | SET | 
 
  | 
| 912 | OVARY (BR98) | BRE1;13 | SET | 
 
  | 
| 913 | UTERUS (BR98) | BRE1;14 | SET | 
 
  | 
| 914 | PROSTATE (BR98) | BRE1;15 | SET | 
 
  | 
| 915 | OTHER (BR98) | BRE1;16 | SET | 
 
  | 
| 916 | HORMONE REPLACEMENT TPY (BR98) | BRE1;17 | SET | 
 
  | 
| 917 | HORMONE REPLACEMENT YRS (BR98) | BRE1;18 | SET | 
 
  | 
| 918 | UNKNOWN MAMMOGRAM (BR98) | BRE1;19 | SET | 
 
  | 
| 919 | UNKNOWN MAMMOGRAM DT (BR98) | BRE1;20 | DATE | 
  | 
| 920 | SCREENING MAMMOGRAM (BR98) | BRE1;21 | SET | 
 
  | 
| 921 | SCREENING MAMMOGRAM DT (BR98) | BRE1;22 | DATE | 
  | 
| 922 | DIAGNOSTIC MAMMOGRAM (BR98) | BRE1;23 | SET | 
 
  | 
| 923 | DIAGNOSTIC MAMMOGRAM DT (BR98) | BRE1;24 | DATE | 
  | 
| 924 | MAGNIFICATION MAMMOGRAM (BR98) | BRE1;25 | SET | 
 
  | 
| 925 | MAGNIFICATION MAMM DT (BR98) | BRE1;26 | DATE | 
  | 
| 926 | MAMMOGRAM (BR98) | BRE1;27 | SET | 
 
  | 
| 927 | ULTRASOUND (BR98) | BRE1;28 | SET | 
 
  | 
| 928 | MOST DEFINITIVE MAMM (BR98) | BRE1;29 | SET | 
 
  | 
| 929 | DATE OF PATHOLOGIC DX (BR98) | BRE1;30 | DATE | 
  | 
| 930 | DCSI ALSO PRESENT (BR98) | BRE1;31 | FREE TEXT | 
  | 
| 931 | ARCHITECTURE PATTERN (BR98) | BRE1;32 | SET | 
 
  | 
| 932 | NUCLEAR GRADE (BR98) | BRE1;33 | SET | 
 
  | 
| 933 | SKIN INVOLVEMENT (BR98) | BRE1;34 | SET | 
 
  | 
| 934 | CHEST WALL INVOLVEMENT (BR98) | BRE1;35 | SET | 
 
  | 
| 935 | PECTORAL INVOLVEMENT (BR98) | BRE1;36 | SET | 
 
  | 
| 936 | DERMAL/LYMPHATIC INV (BR98) | BRE1;37 | SET | 
 
  | 
| 937 | DNA INDEX/PLOIDY (BR98) | BRE1;38 | SET | 
 
  | 
| 940 | ANDROGEN RECEPTOR (BR98) | BRE1;41 | SET | 
 
  | 
| 941 | TYPE OF TEST (BR98) | BRE1;42 | SET | 
 
  | 
| 942 | SIZE OF DCIS TUMOR (MM) (BR98) | BRE1;43 | NUMBER | 
  | 
| 943 | SENTINEL NODE BIOPSY | BRE1;44 | SET | 
 
  | 
| 944 | SENTINEL NODES EXAMINED (BR98) | BRE1;45 | SET | 
 
  | 
| 945 | SENTINEL NODES POSITIVE (BR98) | BRE1;46 | SET | 
 
  | 
| 946 | SENTINEL NODES DETECTED (BR98) | BRE1;47 | SET | 
 
  | 
| 947 | SPECIMEN RADIOGRAPH (BR98) | BRE1;48 | SET | 
 
  | 
| 948 | SUBMITTED TO PATHOLOGY (BR98) | BRE1;49 | SET | 
 
  | 
| 949 | MARGIN DISTANCE (BR98) | BRE1;50 | SET | 
 
  | 
| 950 | RE-EXCISION (BR98) | BRE1;51 | SET | 
 
  | 
| 951 | MICROSCOPIC STATUS (BR98) | BRE1;52 | SET | 
 
  | 
| 952 | PRE-RADIATION MAMMOGRAM (BR98) | BRE1;53 | SET | 
 
  | 
| 953 | SITES IRRADIATED (BR98) | BRE1;54 | SET | 
 
  | 
| 954 | cGy DOSE TO BREAST (BR98) | BRE1;55 | NUMBER | 
  | 
| 955 | SPECIFIC HORMONE THPY (BR98) | BRE1;56 | SET | 
 
  | 
| 956 | CHEMOTHERAPY REGIME (BR98) | BRE1;57 | SET | 
 
  | 
| 993 | REGIONAL TX MODALITY CONV FLAG | 27;7 | SET | 
 
  | 
| 994 | TYPE OF FIRST RECUR CONV FLAG | 27;6 | SET | 
 
  | 
| 995 | STAGED BY CONV FLAG | 27;5 | SET | 
 
  | 
| 996 | SURGICAL MARGINS CONV FLAG | 27;2 | SET | 
 
  | 
| 997 | STAGE FLAG | 27;1 | SET | 
 
  | 
| 998 | SCOPE OF LN SURGERY CONV FLAG | 27;3 | SET | 
 
  | 
| 999 | SURGICAL PROC/OTHER CONV FLAG | 27;4 | SET | 
 
  | 
| 999.1 | DATE OF DIAGNOSIS FLAG | 27;8 | NUMBER | 
  | 
| 999.11 | RX DATE SURG DISCH FLAG | 27;17 | NUMBER | 
  | 
| 999.12 | RX DATE-RADIATION FLAG | 27;18 | NUMBER | 
  | 
| 999.13 | RX DATE RAD ENDED FLAG | 27;19 | NUMBER | 
  | 
| 999.14 | RX DATE SYSTEMIC FLAG | 27;20 | NUMBER | 
  | 
| 999.15 | RX DATE-CHEMO FLAG | 27;21 | NUMBER | 
  | 
| 999.16 | RX DATE-HORMONE FLAG | 27;22 | NUMBER | 
  | 
| 999.17 | RX DATE-BRM FLAG | 27;23 | NUMBER | 
  | 
| 999.18 | RX DATE-OTHER FLAG | 27;24 | NUMBER | 
  | 
| 999.19 | RX DATE-DX/STG PROC FLAG | 27;25 | NUMBER | 
  | 
| 999.2 | DATE CONCLUSIVE DX FLAG | 27;9 | NUMBER | 
  | 
| 999.21 | RECURRENCE DATE-1ST FLAG | 27;26 | NUMBER | 
  | 
| 999.22 | DATE OF LAST CONTACT FLAG | 27;27 | NUMBER | 
  | 
| 999.23 | SUBSQ RX 2ND CRS DATE FLAG | 27;28 | NUMBER | 
  | 
| 999.24 | SUBSQ RX 3RD CRS DATE FLAG | 27;29 | NUMBER | 
  | 
| 999.25 | SUBSQ RX 4TH CRS DATE FLAG | 27;30 | NUMBER | 
  | 
| 999.26 | ADDRESS AT DX--STATE | 27;31 | FREE TEXT | 
  | 
| 999.27 | ADDRESS AT DX--COUNTRY | 27;32 | FREE TEXT | 
  | 
| 999.28 | ADDRESS CURRENT--STATE | 27;33 | FREE TEXT | 
  | 
| 999.289 | ADDRESS CURRENT--POSTAL CODE | 27;35 | FREE TEXT | 
  | 
| 999.29 | ADDRESS CURRENT--COUNTRY | 27;34 | FREE TEXT | 
  | 
| 999.3 | DATE OF MULT TUMORS FLAG | 27;10 | NUMBER | 
  | 
| 999.4 | DATE OF FIRST CONTACT FLAG | 27;11 | NUMBER | 
  | 
| 999.5 | DATE OF INPT ADM FLAG | 27;12 | NUMBER | 
  | 
| 999.6 | DATE OF INPT DISCH FLAG | 27;13 | NUMBER | 
  | 
| 999.7 | DATE 1ST CRS RX FLAG | 27;14 | NUMBER | 
  | 
| 999.8 | RX DATE-SURGERY FLAG | 27;15 | NUMBER | 
  | 
| 999.9 | RX DATE MST DEFN SRG FLAG | 27;16 | NUMBER | 
  | 
| 1000 | ORAL CONTRACEPTIVES | HEP1;1 | SET | 
 
  | 
| 1001 | ESTROGEN REPLACEMENT | HEP1;2 | SET | 
 
  | 
| 1002 | TAMOXIFEN | HEP1;3 | SET | 
 
  | 
| 1003 | OTHER HORMONES | HEP1;4 | SET | 
 
  | 
| 1004 | ASCITES | HEP1;5 | SET | 
 
  | 
| 1005 | CIRRHOSIS | HEP1;6 | SET | 
 
  | 
| 1006 | CHILD'S CLASS A | HEP1;7 | SET | 
 
  | 
| 1007 | CHILD'S CLASS B | HEP1;8 | SET | 
 
  | 
| 1008 | CHILD'S CLASS C | HEP1;9 | SET | 
 
  | 
| 1009 | HEPATITIS B | HEP1;10 | SET | 
 
  | 
| 1010 | HEPATITIS C | HEP1;11 | SET | 
 
  | 
| 1011 | HEMOCHROMATOSIS | HEP1;12 | SET | 
 
  | 
| 1012 | ALCOHOL CONSUMPTION | HEP1;13 | FREE TEXT | 
  | 
| 1013 | AFP (IU/ml) | HEP1;14 | FREE TEXT | 
  | 
| 1014 | CEA (mg/ml) | HEP1;15 | FREE TEXT | 
  | 
| 1015 | CA19.9 (U/ml) | HEP1;16 | FREE TEXT | 
  | 
| 1016 | PROTIME (sec) | HEP1;17 | FREE TEXT | 
  | 
| 1017 | BILIRUBIN (mg/ml) | HEP1;18 | FREE TEXT | 
  | 
| 1018 | ALBUMIN (g/dl) | HEP1;19 | FREE TEXT | 
  | 
| 1019 | LDH (U/I) | HEP1;20 | FREE TEXT | 
  | 
| 1020 | CT ARTERIAL PORT-PERFORMED | HEP1;21 | SET | 
 
  | 
| 1021 | CT ARTERIAL PORT-CIRRHOSIS | HEP1;22 | SET | 
 
  | 
| 1022 | CT ARTERIAL PORT-VASCULAR INV | HEP1;23 | SET | 
 
  | 
| 1023 | CT ARTERIAL PORT-BILOBAR DIS | HEP1;24 | SET | 
 
  | 
| 1024 | CT ARTERIAL PORT-LYMPH NODES | HEP1;25 | SET | 
 
  | 
| 1025 | CT ARTERIAL PORT-SIZE OF TUMOR | HEP1;26 | FREE TEXT | 
  | 
| 1026 | CT ARTERIAL PORT-NUM 0F TUMORS | HEP1;27 | FREE TEXT | 
  | 
| 1027 | SPIRAL CT-PERFORMED | HEP1;28 | SET | 
 
  | 
| 1028 | SPIRAL CT-CIRRHOSIS | HEP1;29 | SET | 
 
  | 
| 1029 | SPIRAL CT-VASCULAR INV | HEP1;30 | SET | 
 
  | 
| 1030 | SPIRAL CT-BILOBAR DIS | HEP1;31 | SET | 
 
  | 
| 1031 | SPIRAL CT-LYMPH NODES | HEP1;32 | SET | 
 
  | 
| 1032 | SPIRAL CT-SIZE OF TUMOR | HEP1;33 | FREE TEXT | 
  | 
| 1033 | SPIRAL CT-NUM OF TUMORS | HEP1;34 | FREE TEXT | 
  | 
| 1034 | INCREMENTAL CT-PERFORMED | HEP1;35 | SET | 
 
  | 
| 1035 | INCREMENTAL CT-CIRRHOSIS | HEP1;36 | SET | 
 
  | 
| 1036 | INCREMENTAL CT-VASCULAR INV | HEP1;37 | SET | 
 
  | 
| 1037 | INCREMENTAL CT-BILOBAR DIS | HEP1;38 | SET | 
 
  | 
| 1038 | INCREMENTAL CT-LYMPH NODES | HEP1;39 | SET | 
 
  | 
| 1039 | INCREMENTAL CT-SIZE OF TUMOR | HEP1;40 | FREE TEXT | 
  | 
| 1040 | INCREMENTAL CT-NUM 0F TUMORS | HEP1;41 | FREE TEXT | 
  | 
| 1041 | ULTRASOUND-PERFORMED | HEP1;42 | SET | 
 
  | 
| 1042 | ULTRASOUND-CIRRHOSIS | HEP1;43 | SET | 
 
  | 
| 1043 | ULTRASOUND-VASCULAR INV | HEP1;44 | SET | 
 
  | 
| 1044 | ULTRASOUND-BILOBAR DIS | HEP1;45 | SET | 
 
  | 
| 1045 | ULTRASOUND-LYMPH NODES | HEP1;46 | SET | 
 
  | 
| 1046 | ULTRASOUND-SIZE OF TUMOR | HEP1;47 | FREE TEXT | 
  | 
| 1047 | ULTRASOUND-NUM 0F TUMORS | HEP1;48 | FREE TEXT | 
  | 
| 1048 | MRI-PERFORMED | HEP1;49 | SET | 
 
  | 
| 1049 | MRI-CIRRHOSIS | HEP1;50 | SET | 
 
  | 
| 1050 | MRI-VASCULAR INV | HEP1;51 | SET | 
 
  | 
| 1051 | MRI-BILOBAR DIS | HEP1;52 | SET | 
 
  | 
| 1052 | MRI-LYMPH NODES | HEP1;53 | SET | 
 
  | 
| 1053 | MRI-SIZE OF TUMOR | HEP1;54 | FREE TEXT | 
  | 
| 1054 | MRI-NUM 0F TUMORS | HEP1;55 | FREE TEXT | 
  | 
| 1055 | DEFINITIVE DIAGNOSIS | HEP1;56 | SET | 
 
  | 
| 1056 | RADIO-FREQUENCY DESTRUCTION | HEP1;57 | SET | 
 
  | 
| 1057 | ABLATION & RESECTION | HEP1;58 | SET | 
 
  | 
| 1058 | DISTANCE TO CLOSEST MARGIN | HEP1;59 | SET | 
 
  | 
| 1059 | ABLATION | HEP1;60 | SET | 
 
  | 
| 1060 | RESECTION | HEP1;61 | SET | 
 
  | 
| 1061 | CISPLATIN | HEP1;62 | SET | 
 
  | 
| 1062 | FUDR | HEP1;63 | SET | 
 
  | 
| 1063 | 5-FU | HEP1;64 | SET | 
 
  | 
| 1064 | FU & LEUCOVORIN | HEP1;65 | SET | 
 
  | 
| 1065 | IRINOTECAN (CPT-11) | HEP1;66 | SET | 
 
  | 
| 1066 | MITOMYCIN C | HEP1;67 | SET | 
 
  | 
| 1067 | OXALIPLATIN | HEP1;68 | SET | 
 
  | 
| 1068 | GEMCITABINE | HEP1;69 | SET | 
 
  | 
| 1069 | ROUTE CHEMO ADMIN | HEP1;70 | SET | 
 
  | 
| 1070 | CHEMOTHERAPY/SURGERY SEQUENCE | HEP1;71 | SET | 
 
  | 
| 1071 | ARTERIAL EMBOLIZATION | HEP1;72 | SET | 
 
  | 
| 1072 | DEATH W/I 30 DAYS START TX | HEP1;73 | SET | 
 
  | 
| 1100 | HISTORY OF MELANOMA (PT) | MEL1;1 | SET | 
 
  | 
| 1101 | HISTORY OF OTHER CANCER (PT) | MEL1;2 | SET | 
 
  | 
| 1102 | FIRST SITE CODE | MEL1;3 | POINTER TO ICDO TOPOGRAPHY FILE (#164) | ICDO TOPOGRAPHY(#164)
  | 
| 1103 | FIRST SITE DIAGNOSIS DATE | MEL1;4 | DATE | 
  | 
| 1104 | SECOND SITE CODE | MEL1;5 | POINTER TO ICDO TOPOGRAPHY FILE (#164) | ICDO TOPOGRAPHY(#164)
  | 
| 1105 | SECOND SITE DIAGNOSIS DATE | MEL1;6 | DATE | 
  | 
| 1106 | PREGNANCY AT INITIAL DIAGNOSIS | MEL1;7 | SET | 
 
  | 
| 1107 | EXOGENOUS HORMONES | MEL1;8 | SET | 
 
  | 
| 1108 | DISEASE PRESENTATION LOCATION | MEL1;9 | SET | 
 
  | 
| 1109 | TYPE OF BIOPSY | MEL1;10 | SET | 
 
  | 
| 1110 | EXTRANODAL EXTENSION | MEL1;11 | SET | 
 
  | 
| 1111 | MICROSATELLITOSIS | MEL1;12 | SET | 
 
  | 
| 1112 | NUMBER OF SATELLITE NODULES | MEL1;13 | FREE TEXT | 
  | 
| 1113 | LOCATION OF IN-TRANSIT NODULES | MEL1;14 | SET | 
 
  | 
| 1114 | BRESLOW'S THICKNESS | MEL1;15 | FREE TEXT | 
  | 
| 1115 | CLARK'S LEVEL OF INVASION | MEL1;16 | SET | 
 
  | 
| 1116 | ANGIOLYMPHATIC INVASION | MEL1;17 | SET | 
 
  | 
| 1117 | PERINEURAL INVASION | MEL1;18 | SET | 
 
  | 
| 1118 | ULCERATION | MEL1;19 | SET | 
 
  | 
| 1119 | CLINICALLY AMELANOTIC | MEL1;20 | SET | 
 
  | 
| 1120 | MARGIN DISTANCE (MEL) | MEL1;21 | FREE TEXT | 
  | 
| 1121 | SURGICAL CLOSURE | MEL1;22 | SET | 
 
  | 
| 1122 | PRE-OP LYMPHOSCINTIGRAPHY | MEL1;23 | SET | 
 
  | 
| 1123 | SENTINEL NODES DETECTED BY | MEL1;24 | SET | 
 
  | 
| 1124 | SENTINEL NODES EXAMINED (MEL) | MEL1;25 | SET | 
 
  | 
| 1125 | SENTINEL NODES POSITIVE (MEL) | MEL1;26 | SET | 
 
  | 
| 1126 | METHOD OF PATHOLOGIC EXAM | MEL1;27 | SET | 
 
  | 
| 1127 | LYMPH NODE DISSECTION | MEL1;28 | SET | 
 
  | 
| 1128 | NUMBER OF BASINS DISSECTED | MEL1;29 | SET | 
 
  | 
| 1129 | NUMBER OF BASINS POSITIVE | MEL1;30 | SET | 
 
  | 
| 1130 | INTRAVENOUS THERAPY | MEL1;31 | SET | 
 
  | 
| 1131 | GENE THERAPY | MEL1;32 | SET | 
 
  | 
| 1132 | SIZE OF TUMOR (MELANOMA) | MEL1;33 | NUMBER | 
  | 
| 1200 | HANDEDNESS | CNS1;1 | SET | 
 
  | 
| 1201 | HYPERTENSION | CNS1;2 | SET | 
 
  | 
| 1202 | MULTIPLE SCLEROSIS (MS) | CNS1;3 | SET | 
 
  | 
| 1203 | DIABETES | CNS1;4 | SET | 
 
  | 
| 1204 | CEREBROVASCULAR DISEASE | CNS1;5 | SET | 
 
  | 
| 1205 | BRAIN | CNS1;6 | SET | 
 
  | 
| 1206 | BREAST | CNS1;7 | SET | 
 
  | 
| 1207 | PROSTATE | CNS1;8 | SET | 
 
  | 
| 1208 | MALIGNANT MELANOMA | CNS1;9 | SET | 
 
  | 
| 1209 | OTHER SKIN CANCER | CNS1;10 | SET | 
 
  | 
| 1210 | LEUKEMIA | CNS1;11 | SET | 
 
  | 
| 1211 | COLON OR OTHER GI CANCERS | CNS1;12 | SET | 
 
  | 
| 1212 | OTHER PERSONAL HISTORY OF CA | CNS1;13 | SET | 
 
  | 
| 1213 | NEUROFIBROMATOSIS | CNS1;14 | SET | 
 
  | 
| 1214 | VON HIPPEL-LINDAU DISEASE | CNS1;15 | SET | 
 
  | 
| 1215 | TUBEROUS SCLEROSIS | CNS1;16 | SET | 
 
  | 
| 1216 | TURCOT SYNDROME | CNS1;17 | SET | 
 
  | 
| 1217 | LI-FRAUMENI SYNDROME | CNS1;18 | SET | 
 
  | 
| 1218 | KOWDEN DISEASE | CNS1;19 | SET | 
 
  | 
| 1219 | NEVOID BASAL CELL CARCINOMA | CNS1;20 | SET | 
 
  | 
| 1220 | HEADACHE | CNS1;21 | SET | 
 
  | 
| 1221 | NAUSEA/VOMITING | CNS1;22 | SET | 
 
  | 
| 1222 | CHANGE IN SENSE OF SMELL/TASTE | CNS1;23 | SET | 
 
  | 
| 1223 | ALTERED ALERTNESS | CNS1;24 | SET | 
 
  | 
| 1224 | FATIGUE | CNS1;25 | SET | 
 
  | 
| 1225 | SPEECH DISTURBANCE | CNS1;26 | SET | 
 
  | 
| 1226 | PERSONALITY CHANGES | CNS1;27 | SET | 
 
  | 
| 1227 | DEPRESSION | CNS1;28 | SET | 
 
  | 
| 1228 | MEMORY LOSS | CNS1;29 | SET | 
 
  | 
| 1229 | LACK OF CONCENTRATION | CNS1;30 | SET | 
 
  | 
| 1230 | DOUBLE VISION | CNS1;31 | SET | 
 
  | 
| 1231 | OTHER VISUAL DISTURBANCE | CNS1;32 | SET | 
 
  | 
| 1232 | DECREASED HEARING | CNS1;33 | SET | 
 
  | 
| 1233 | VERTIGO | CNS1;34 | SET | 
 
  | 
| 1234 | TINNITUS | CNS1;35 | SET | 
 
  | 
| 1235 | NUMBNESS/TINGLING | CNS1;36 | SET | 
 
  | 
| 1236 | WEAKNESS OR PARALYSIS | CNS1;37 | SET | 
 
  | 
| 1237 | DIFFICULTY IN COORD/BALANCE | CNS1;38 | SET | 
 
  | 
| 1238 | GENERALIZED SEIZURE | CNS1;39 | SET | 
 
  | 
| 1239 | FOCAL SEIZURE | CNS1;40 | SET | 
 
  | 
| 1240 | BLADDER INCONTINENCE | CNS1;41 | SET | 
 
  | 
| 1241 | BOWEL INCONTINENCE | CNS1;42 | SET | 
 
  | 
| 1242 | PAIN (OTHER THAN HEADACHE) | CNS1;43 | SET | 
 
  | 
| 1243 | WEIGHT CHANGE | CNS1;44 | SET | 
 
  | 
| 1244 | OTHER SYMPTOMS | CNS1;45 | SET | 
 
  | 
| 1245 | ALERTNESS | CNS1;46 | SET | 
 
  | 
| 1246 | SPEECH | CNS1;47 | SET | 
 
  | 
| 1247 | PERSONALITY | CNS1;48 | SET | 
 
  | 
| 1248 | MEMORY OR JUDGEMENT | CNS1;49 | SET | 
 
  | 
| 1249 | VISUAL ACUITY | CNS1;50 | SET | 
 
  | 
| 1250 | VISUAL FIELDS | CNS1;51 | SET | 
 
  | 
| 1251 | EYE MOVEMENTS (EOM) | CNS1;52 | SET | 
 
  | 
| 1252 | FACIAL SENSATION | CNS1;53 | SET | 
 
  | 
| 1253 | FACIAL MOVEMENT | CNS1;54 | SET | 
 
  | 
| 1254 | HEARING | CNS1;55 | SET | 
 
  | 
| 1255 | GAG REFLEX | CNS1;56 | SET | 
 
  | 
| 1256 | STERNOCLEIDOMASTOID/SHLD STR | CNS1;57 | SET | 
 
  | 
| 1257 | ARTICULATION OR ENUNCIATION | CNS1;58 | SET | 
 
  | 
| 1258 | PAPILLEDEMA | CNS1;59 | SET | 
 
  | 
| 1259 | TONGUE FASCICULATIONS/ATROPHY | CNS1;60 | SET | 
 
  | 
| 1260 | DECREASE IN SENSATION/ANY SITE | CNS1;61 | SET | 
 
  | 
| 1261 | CORTICAL SENSORY DEFICIT | CNS1;62 | SET | 
 
  | 
| 1262 | WEAKNESS/ATROPHY/FASCICULATION | CNS1;63 | SET | 
 
  | 
| 1263 | ATAXIA OF GAIT | CNS1;64 | SET | 
 
  | 
| 1264 | TRUNCAL ATAXIA | CNS1;65 | SET | 
 
  | 
| 1265 | DYSMETRIA | CNS1;66 | SET | 
 
  | 
| 1266 | RAPID ALTERNATING MOVEMENTS | CNS1;67 | SET | 
 
  | 
| 1267 | FINGER TO FINGER NOSE TESTING | CNS1;68 | SET | 
 
  | 
| 1268 | HEEL TO KNEE TO SHIN TESTING | CNS1;69 | SET | 
 
  | 
| 1269 | DEEP TENDON REFLEXES/UPPER EXT | CNS1;70 | SET | 
 
  | 
| 1270 | DEEP TENDON REFLEXES/LOWER EXT | CNS1;71 | SET | 
 
  | 
| 1271 | BABINSKI SIGN | CNS1;72 | SET | 
 
  | 
| 1272 | HOFFMAN REFLEX | CNS1;73 | SET | 
 
  | 
| 1273 | OTHER ABNORMAL REFLEXES | CNS1;74 | SET | 
 
  | 
| 1274 | ANGIOGRAPHY | CNS1;75 | SET | 
 
  | 
| 1275 | COMPUTED TOMOGRAPHY (CT) SCAN | CNS1;76 | SET | 
 
  | 
| 1276 | CT SCAN OF SPINE | CNS1;77 | SET | 
 
  | 
| 1277 | ELECTROENCEPHALOGRAPHY (EEG) | CNS1;78 | SET | 
 
  | 
| 1278 | ISOTOPE BRAIN SCAN | CNS1;79 | SET | 
 
  | 
| 1279 | POSITRON EMISSION TOMOGRAPHY | CNS1;80 | SET | 
 
  | 
| 1280 | SPECT SCAN | CNS1;81 | SET | 
 
  | 
| 1281 | MRI OF BRAIN | CNS1;82 | SET | 
 
  | 
| 1282 | MRI OF SPINE | CNS1;83 | SET | 
 
  | 
| 1283 | FUNCTIONAL MRI | CNS1;84 | SET | 
 
  | 
| 1284 | MYELOGRAPHY | CNS1;85 | SET | 
 
  | 
| 1285 | MAGNETIC RES SPECTROSCOPY | CNS1;86 | SET | 
 
  | 
| 1286 | FRONTAL LOBE | CNS2;1 | SET | 
 
  | 
| 1287 | TEMPORAL LOBE | CNS2;2 | SET | 
 
  | 
| 1288 | PARIETAL LOBE | CNS2;3 | SET | 
 
  | 
| 1289 | OCCIPITAL LOBE | CNS2;4 | SET | 
 
  | 
| 1290 | OPTIC NERVES | CNS2;5 | SET | 
 
  | 
| 1291 | PITUITARY GLAND | CNS2;6 | SET | 
 
  | 
| 1292 | PINEAL GLAND | CNS2;7 | SET | 
 
  | 
| 1293 | CEREBELLUM | CNS2;8 | SET | 
 
  | 
| 1294 | BRAIN STEM | CNS2;9 | SET | 
 
  | 
| 1295 | SKULL BASE | CNS2;10 | SET | 
 
  | 
| 1296 | OTHER SKULL | CNS2;11 | SET | 
 
  | 
| 1297 | SPINAL CORD | CNS2;12 | SET | 
 
  | 
| 1298 | CEREBRAL SPINAL FLUID (CSF) | CNS2;13 | SET | 
 
  | 
| 1299 | CRANIAL MENINGES | CNS2;14 | SET | 
 
  | 
| 1300 | SPINAL MENINGES | CNS2;15 | SET | 
 
  | 
| 1301 | OTHER TUMOR LOC/INVOLVEMENT | CNS2;16 | SET | 
 
  | 
| 1302 | LEFT | CNS2;17 | SET | 
 
  | 
| 1303 | RIGHT | CNS2;18 | SET | 
 
  | 
| 1304 | MIDLINE | CNS2;19 | SET | 
 
  | 
| 1305 | NUMBER OF TUMORS | CNS2;20 | SET | 
 
  | 
| 1306 | DATE OF FIRST SYMPTOMS | CNS2;21 | DATE | 
  | 
| 1307 | DATE OF PATHOLOGIC DIAGNOSIS | CNS2;22 | DATE | 
  | 
| 1308 | WHO HISTOLOGICAL CL | CNS2;23 | POINTER TO WHO HISTOLOGICAL CLASSIFICATION FILE (#164.9) | WHO HISTOLOGICAL CLASSIFICATION(#164.9)
  | 
| 1309 | MOLECULAR MARKERS | CNS2;24 | SET | 
 
  | 
| 1310 | TUMOR SIZE (SOURCE) | CNS2;25 | SET | 
 
  | 
| 1311 | KARNOFSKY'S RATING PRIOR TO TX | CNS2;26 | POINTER TO KARNOFSKY'S RATING FILE (#164.17) | KARNOFSKY'S RATING(#164.17)
  | 
| 1312 | PROTOCOL PARTICIPATION (CNS) | CNS2;27 | SET | 
 
  | 
| 1313 | PROTOCOL PHASE | CNS2;28 | SET | 
 
  | 
| 1314 | NONE, NO NON-CA DIR SURGERY | CNS2;29 | SET | 
 
  | 
| 1315 | VENTRICULOSTOMY/EXT VENT DRAIN | CNS2;30 | SET | 
 
  | 
| 1316 | CSF SHUNT/VENTRICULOPERITONEAL | CNS2;31 | SET | 
 
  | 
| 1317 | CSF SHUNT/3RD VENTRICULOSTOMY | CNS2;32 | SET | 
 
  | 
| 1318 | CSF SHUNT/OTHER | CNS2;33 | SET | 
 
  | 
| 1319 | STEREOTACTIC BIOPSY | CNS2;34 | SET | 
 
  | 
| 1320 | OPEN BRAIN BIOPSY | CNS2;35 | SET | 
 
  | 
| 1321 | OPEN BX OF SPINCAL CORD TUMOR | CNS2;36 | SET | 
 
  | 
| 1322 | LAMINECTOMY W/O RESECT/DURA | CNS2;37 | SET | 
 
  | 
| 1323 | LAMINECTOMY W/O RESECT W DURA | CNS2;38 | SET | 
 
  | 
| 1324 | SURGERY, NOS | CNS2;39 | SET | 
 
  | 
| 1325 | UNKNOWN IF SURGERY DONE | CNS2;40 | SET | 
 
  | 
| 1326 | SURGICAL APPROACH (CNS) | CNS2;41 | SET | 
 
  | 
| 1327 | EXTENT OF SURGICAL RESECTION | CNS2;42 | SET | 
 
  | 
| 1328 | SIZE OF RESIDUAL TUMOR | CNS2;43 | NUMBER | 
  | 
| 1329 | SIZE OF RES TUMOR (SOURCE) | CNS2;44 | SET | 
 
  | 
| 1330 | ANESTHETIC PROBLEM | CNS2;45 | SET | 
 
  | 
| 1331 | HEMORRHAGE AT OPERATIVE SITE | CNS2;46 | SET | 
 
  | 
| 1332 | SEIZURE | CNS2;47 | SET | 
 
  | 
| 1333 | INFECTION(S) | CNS2;48 | SET | 
 
  | 
| 1334 | DVT (DEEP VENOUS THROMBOSIS) | CNS2;49 | SET | 
 
  | 
| 1335 | PERSISTENT NEUROL WORSENING | CNS2;50 | SET | 
 
  | 
| 1336 | TOTAL RADIATION DOSE (cGy) | CNS2;51 | SET | 
 
  | 
| 1337 | TYPE OF EXT BEAM RADIATION | CNS2;52 | SET | 
 
  | 
| 1338 | INTERSTITIAL RAD/BRACHYTHERAPY | CNS2;53 | SET | 
 
  | 
| 1339 | STEREOTACTIC RADIOSURGERY | CNS2;54 | SET | 
 
  | 
| 1340 | SKIN REACTIONS | CNS2;55 | SET | 
 
  | 
| 1341 | ANOREXIA | CNS2;56 | SET | 
 
  | 
| 1342 | NAUSEA OR VOMITING | CNS2;57 | SET | 
 
  | 
| 1343 | FATIGUE | CNS2;58 | SET | 
 
  | 
| 1344 | NEUROLOGIC WORSENING | CNS2;59 | SET | 
 
  | 
| 1345 | RADIATION THERAPY | CNS2;60 | SET | 
 
  | 
| 1346 | PROCARBAZINE | CNS2;61 | SET | 
 
  | 
| 1347 | CCNU | CNS2;62 | SET | 
 
  | 
| 1348 | VINCRISTINE | CNS2;63 | SET | 
 
  | 
| 1349 | HYDROXYUREA | CNS2;64 | SET | 
 
  | 
| 1350 | BCNU | CNS2;65 | SET | 
 
  | 
| 1351 | BCNU WAFER IMPLANT | CNS2;66 | SET | 
 
  | 
| 1352 | VP-16 | CNS2;67 | SET | 
 
  | 
| 1353 | CARBOPLATIN | CNS2;68 | SET | 
 
  | 
| 1354 | TEMOZOLOMIDE | CNS2;69 | SET | 
 
  | 
| 1355 | CPT-11 | CNS2;70 | SET | 
 
  | 
| 1356 | TAMOXIFEN | CNS2;71 | SET | 
 
  | 
| 1357 | CYTARABINE (ARA-C) | CNS2;72 | SET | 
 
  | 
| 1358 | CHEMOTHERAPEUTIC ROUTE | CNS2;73 | SET | 
 
  | 
| 1359 | HEARING LOSS | CNS2;74 | SET | 
 
  | 
| 1360 | INFECTION | CNS2;75 | SET | 
 
  | 
| 1361 | NAUSEA AND VOMITING | CNS2;76 | SET | 
 
  | 
| 1362 | BLOOD COUNT DROP/BLEEDING | CNS2;77 | SET | 
 
  | 
| 1363 | PERIPHERAL NEUROPATHY | CNS2;78 | SET | 
 
  | 
| 1364 | RENAL FAILURE | CNS2;79 | SET | 
 
  | 
| 1365 | PULMONARY TOXICITY | CNS2;80 | SET | 
 
  | 
| 1366 | OTHER CHEMO COMPLICATIONS | CNS2;81 | SET | 
 
  | 
| 1367 | KARNOFSKY'S RATING @ DIS/TRANS | CNS2;82 | POINTER TO KARNOFSKY'S RATING FILE (#164.17) | KARNOFSKY'S RATING(#164.17)
  | 
| 1368 | DATE OF PROGRESSION | CNS2;83 | DATE | 
  | 
| 1369 | TYPE OF PROGRESSION | CNS2;84 | SET | 
 
  | 
| 1370 | RECURRENCE/PROGRESSION DOC | CNS2;85 | SET | 
 
  | 
| 1371 | KARNOFSKY'S RATING RECURRENCE | CNS2;86 | POINTER TO KARNOFSKY'S RATING FILE (#164.17) | KARNOFSKY'S RATING(#164.17)
  | 
| 1372 | TYPE OF 1ST RECURRENCE/CNS | CNS2;87 | SET | 
 
  | 
| 1373 | PROTOCOL PARTICIPATION (SUBTX) | CNS2;88 | SET | 
 
  | 
| 1374 | TYPE OF SUBSEQUENT SURGICAL TX | CNS2;89 | SET | 
 
  | 
| 1375 | TYPE OF SUBSEQUENT RADIATION | CNS2;90 | SET | 
 
  | 
| 1376 | PROCARBAZINE (SUB TX) | CNS3;1 | SET | 
 
  | 
| 1377 | CCNU (SUB TX) | CNS3;2 | SET | 
 
  | 
| 1378 | VINCRISTINE (SUB TX) | CNS3;3 | SET | 
 
  | 
| 1379 | HYDROXYUREA (SUB TX) | CNS3;4 | SET | 
 
  | 
| 1380 | METHOTREXATE (SUB TX) | CNS3;5 | SET | 
 
  | 
| 1381 | CISPLATIN (SUB TX) | CNS3;6 | SET | 
 
  | 
| 1382 | BCNU (SUB TX) | CNS3;7 | SET | 
 
  | 
| 1383 | BCNU WAFER IMPLANT (SUB TX) | CNS3;8 | SET | 
 
  | 
| 1384 | VP-16 (SUB TX) | CNS3;9 | SET | 
 
  | 
| 1385 | CARBOPLATIN (SUB TX) | CNS3;10 | SET | 
 
  | 
| 1386 | TEMOZOLOMIDE (SUB TX) | CNS3;11 | SET | 
 
  | 
| 1387 | CYCLOPHOSPHAMIDE (SUB TX) | CNS3;12 | SET | 
 
  | 
| 1388 | CPT-11 (SUB TX) | CNS3;13 | SET | 
 
  | 
| 1389 | TAMOXIFEN (SUB TX) | CNS3;14 | SET | 
 
  | 
| 1390 | INTERFERON (SUB TX) | CNS3;15 | SET | 
 
  | 
| 1391 | CYTARABINE (ARA-C) (SUB TX) | CNS3;16 | SET | 
 
  | 
| 1392 | OTHER CHEMOTHERAPY (SUB TX) | CNS3;17 | SET | 
 
  | 
| 1393 | OTHER SUBSEQUENT TREATMENT | CNS3;18 | SET | 
 
  | 
| 1394 | TUMOR SIZE | CNS3;19 | NUMBER | 
  | 
| 1400 | LNG CO-MORBID CONDITION 1 | LUN1;1 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1400.1 | LNG CO-MORBID CONDITION 2 | LUN1;2 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1400.2 | LNG CO-MORBID CONDITION 3 | LUN1;3 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1400.3 | LNG CO-MORBID CONDITION 4 | LUN1;4 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1400.4 | LNG CO-MORBID CONDITION 5 | LUN1;5 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1400.5 | LNG CO-MORBID CONDITION 6 | LUN1;6 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1400.6 | LNG CO-MORBID CONDITION Y/N | LUN1;76 | SET | ************************REQUIRED FIELD************************ 
 
  | 
| 1401 | LNG DURATION OF TOBACCO USE | LUN1;7 | FREE TEXT | 
  | 
| 1402 | LNG DATE OF FIRST TISSUE DX | LUN1;8 | DATE | 
  | 
| 1403 | LNG PERSONAL HIST OTH MALIG | LUN1;9 | POINTER TO ICDO TOPOGRAPHY FILE (#164) | ICDO TOPOGRAPHY(#164)
  | 
| 1404 | LNG COUGH | LUN1;10 | SET | 
 
  | 
| 1404.1 | LNG SHORTNESS OF BREATH | LUN1;11 | SET | 
 
  | 
| 1404.2 | LNG WEIGHT LOSS | LUN1;12 | SET | 
 
  | 
| 1404.3 | LNG HEMOPTYSIS | LUN1;13 | SET | 
 
  | 
| 1404.4 | LNG PALPABLE LYMPH NODES | LUN1;14 | SET | 
 
  | 
| 1405 | LNG CHEST X-RAY | LUN1;15 | SET | 
 
  | 
| 1405.1 | LNG CT SCAN | LUN1;16 | SET | 
 
  | 
| 1405.2 | LNG BRONCHOSCOPY | LUN1;17 | SET | 
 
  | 
| 1406 | LNG HISTORY AND PHYSICAL | LUN1;18 | SET | 
 
  | 
| 1406.1 | LNG BRONCHOSCOPY PRE-THERAPY | LUN1;19 | SET | 
 
  | 
| 1406.2 | LNG FNAB | LUN1;20 | SET | 
 
  | 
| 1406.3 | LNG MEDIASTINOSCOPY | LUN1;21 | SET | 
 
  | 
| 1406.4 | LNG THOROCOTOMY/OPEN BIOPSY | LUN1;22 | SET | 
 
  | 
| 1406.5 | LNG VATS | LUN1;23 | SET | 
 
  | 
| 1407 | LNG FVC | LUN1;24 | NUMBER | 
  | 
| 1407.1 | LNG FEV | LUN1;25 | NUMBER | 
  | 
| 1408 | LNG LIVER FUNCTION TESTS | LUN1;26 | SET | 
 
  | 
| 1409 | LNG BONE SCAN | LUN1;27 | SET | 
 
  | 
| 1409.1 | LNG EMPHYSEMA (BONE SCAN) | LUN1;28 | SET | 
 
  | 
| 1409.2 | LNG VASCULAR INV (BONE SCAN) | LUN1;29 | SET | 
 
  | 
| 1409.3 | LNG MEDIASTINAL LN (BONE SCAN) | LUN1;30 | SET | 
 
  | 
| 1409.4 | LNG TUMOR SIZE (BONE SCAN) | LUN1;31 | FREE TEXT | 
  | 
| 1409.5 | LNG NUM OF TUMORS (BONE SCAN) | LUN1;32 | FREE TEXT | 
  | 
| 1409.6 | LNG METASTASIS (BONE SCAN) | LUN1;33 | SET | 
 
  | 
| 1410 | LNG CT SCAN OF CHEST | LUN1;34 | SET | 
 
  | 
| 1410.1 | LNG EMPHYSEMA (CHEST CT) | LUN1;35 | SET | 
 
  | 
| 1410.2 | LNG VASCULAR INV (CHEST CT) | LUN1;36 | SET | 
 
  | 
| 1410.3 | LNG MEDIASTINAL LN (CHEST CT) | LUN1;37 | SET | 
 
  | 
| 1410.4 | LNG TUMOR SIZE (CHEST CT) | LUN1;38 | FREE TEXT | 
  | 
| 1410.5 | LNG NUM OF TUMORS (CHEST CT) | LUN1;39 | FREE TEXT | 
  | 
| 1410.6 | LNG METASTASIS (CHEST CT) | LUN1;40 | SET | 
 
  | 
| 1411 | LNG CT SCAN OF BRAIN | LUN1;41 | SET | 
 
  | 
| 1411.1 | LNG EMPHYSEMA (BRAIN CT) | LUN1;42 | SET | 
 
  | 
| 1411.2 | LNG VASCULAR INV (BRAIN CT) | LUN1;43 | SET | 
 
  | 
| 1411.3 | LNG MEDIASTINAL LN (BRAIN CT) | LUN1;44 | SET | 
 
  | 
| 1411.4 | LNG TUMOR SIZE (BRAIN CT) | LUN1;45 | FREE TEXT | 
  | 
| 1411.5 | LNG NUM OF TUMORS (BRAIN CT) | LUN1;46 | FREE TEXT | 
  | 
| 1411.6 | LNG METASTASIS (BRAIN CT) | LUN1;47 | SET | 
 
  | 
| 1412 | LNG MRI SCAN OF CHEST | LUN1;48 | SET | 
 
  | 
| 1412.1 | LNG EMPHYSEMA (CHEST MRI) | LUN1;49 | SET | 
 
  | 
| 1412.2 | LNG VASCULAR INV (CHEST MRI) | LUN1;50 | SET | 
 
  | 
| 1412.3 | LNG MEDIASTINAL LN (CHEST MRI) | LUN1;51 | SET | 
 
  | 
| 1412.4 | LNG TUMOR SIZE (CHEST MRI) | LUN1;52 | FREE TEXT | 
  | 
| 1412.5 | LNG NUM OF TUMORS (CHEST MRI) | LUN1;53 | FREE TEXT | 
  | 
| 1412.6 | LNG METASTASIS (CHEST MRI) | LUN1;54 | SET | 
 
  | 
| 1413 | LNG MRI SCAN OF BRAIN | LUN1;55 | SET | 
 
  | 
| 1413.1 | LNG EMPHYSEMA (BRAIN MRI) | LUN1;56 | SET | 
 
  | 
| 1413.2 | LNG VASCULAR INV (BRAIN MRI) | LUN1;57 | SET | 
 
  | 
| 1413.3 | LNG MEDIASTINAL LN (BRAIN MRI) | LUN1;58 | SET | 
 
  | 
| 1413.4 | LNG TUMOR SIZE (BRAIN MRI) | LUN1;59 | FREE TEXT | 
  | 
| 1413.5 | LNG NUM OF TUMORS (BRAIN MRI) | LUN1;60 | FREE TEXT | 
  | 
| 1413.6 | LNG METASTASIS (BRAIN MRI) | LUN1;61 | SET | 
 
  | 
| 1414 | LNG PET SCAN | LUN1;62 | SET | 
 
  | 
| 1414.1 | LNG EMPHYSEMA (PET SCAN) | LUN1;63 | SET | 
 
  | 
| 1414.2 | LNG VASCULAR INV (PET SCAN) | LUN1;64 | SET | 
 
  | 
| 1414.3 | LNG MEDIASTINAL LN (PET SCAN) | LUN1;65 | SET | 
 
  | 
| 1414.4 | LNG TUMOR SIZE (PET SCAN) | LUN1;66 | FREE TEXT | 
  | 
| 1414.5 | LNG NUM OF TUMORS (PET SCAN) | LUN1;67 | FREE TEXT | 
  | 
| 1414.6 | LNG METASTASIS (PET SCAN) | LUN1;68 | SET | 
 
  | 
| 1415 | LNG X-RAY OF CHEST | LUN1;69 | SET | 
 
  | 
| 1415.1 | LNG EMPHYSEMA (CHEST XRAY) | LUN1;70 | SET | 
 
  | 
| 1415.2 | LNG VASCULAR INV (CHEST XRAY) | LUN1;71 | SET | 
 
  | 
| 1415.3 | LNG MEDIASTINAL (CHEST XRAY) | LUN1;72 | SET | 
 
  | 
| 1415.4 | LNG TUMOR SIZE (CHEST XRAY) | LUN1;73 | FREE TEXT | 
  | 
| 1415.5 | LNG NUM OF TUMORS (CHEST XRAY) | LUN1;74 | FREE TEXT | 
  | 
| 1415.6 | LNG METASTASIS (CHEST XRAY) | LUN1;75 | SET | 
 
  | 
| 1416 | LNG HIGH MEDIASTINAL (PRE-OP) | LUN2;1 | SET | 
 
  | 
| 1416.1 | LNG UPPER PARATRACH (PRE-OP) | LUN2;2 | SET | 
 
  | 
| 1416.2 | LNG PREVASC/RETRO (PRE-OP) | LUN2;3 | SET | 
 
  | 
| 1416.3 | LNG LOWER PARATRACH (PRE-OP) | LUN2;4 | SET | 
 
  | 
| 1416.4 | LNG SUBAORTIC (PRE-OP) | LUN2;5 | SET | 
 
  | 
| 1416.5 | LNG PARAORTIC (PRE-OP) | LUN2;6 | SET | 
 
  | 
| 1416.6 | LNG SUBCARINAL (PRE-OP) | LUN2;7 | SET | 
 
  | 
| 1416.7 | LNG PARAESOPHAGEAL (PRE-OP) | LUN2;8 | SET | 
 
  | 
| 1416.8 | LNG PULMONARY LIG (PRE-OP) | LUN2;9 | SET | 
 
  | 
| 1417 | LNG FROZEN SECTION | LUN2;10 | SET | 
 
  | 
| 1418 | LNG VASCULAR INVASION | LUN2;11 | SET | 
 
  | 
| 1418.1 | LNG LYMPHATICS INVASION | LUN2;12 | SET | 
 
  | 
| 1418.2 | LNG PLEURA INVASION | LUN2;13 | SET | 
 
  | 
| 1418.3 | LNG CHEST WALL INVASION | LUN2;14 | SET | 
 
  | 
| 1418.4 | LNG OTHER INVASION | LUN2;15 | SET | 
 
  | 
| 1419 | LNG HIGH MEDIASTINAL (SCOPE) | LUN2;16 | SET | 
 
  | 
| 1419.1 | LNG UPPER PARATRACHEAL (SCOPE) | LUN2;17 | SET | 
 
  | 
| 1419.2 | LNG PREVASC/RETROTRACH (SCOPE) | LUN2;18 | SET | 
 
  | 
| 1419.3 | LNG LOWER PARATRACHEAL (SCOPE) | LUN2;19 | SET | 
 
  | 
| 1419.4 | LNG SUBAORTIC (SCOPE) | LUN2;20 | SET | 
 
  | 
| 1419.5 | LNG PARAORTIC (SCOPE) | LUN2;21 | SET | 
 
  | 
| 1419.6 | LNG SUBCARINAL (SCOPE) | LUN2;22 | SET | 
 
  | 
| 1419.7 | LNG PARAESOPHAGEAL (SCOPE) | LUN2;23 | SET | 
 
  | 
| 1419.8 | LNG PULMONARY LIGAMENT (SCOPE) | LUN2;24 | SET | 
 
  | 
| 1420 | LNG PERI-OPERATIVE BLOOD REP | LUN2;25 | FREE TEXT | 
  | 
| 1421 | LNG PERI-OPERATIVE DEATH | LUN2;26 | SET | 
 
  | 
| 1422 | LNG BOOST DOSE (cGy) | LUN2;27 | FREE TEXT | 
  | 
| 1423 | CHEMOTHERAPEUTIC AGENT #1 | LUN2;28 | POINTER TO CHEMOTHERAPEUTIC DRUGS FILE (#164.18) | CHEMOTHERAPEUTIC DRUGS(#164.18)
  | 
| 1423.1 | CHEMOTHERAPEUTIC AGENT #2 | LUN2;29 | POINTER TO CHEMOTHERAPEUTIC DRUGS FILE (#164.18) | CHEMOTHERAPEUTIC DRUGS(#164.18)
  | 
| 1423.2 | CHEMOTHERAPEUTIC AGENT #3 | LUN2;30 | POINTER TO CHEMOTHERAPEUTIC DRUGS FILE (#164.18) | CHEMOTHERAPEUTIC DRUGS(#164.18)
  | 
| 1423.3 | CHEMOTHERAPEUTIC AGENT #4 | LUN2;44 | POINTER TO CHEMOTHERAPEUTIC DRUGS FILE (#164.18) | CHEMOTHERAPEUTIC DRUGS(#164.18)
  | 
| 1423.4 | CHEMOTHERAPEUTIC AGENT #5 | LUN2;45 | POINTER TO CHEMOTHERAPEUTIC DRUGS FILE (#164.18) | CHEMOTHERAPEUTIC DRUGS(#164.18)
  | 
| 1424 | LNG CHEMOTHERAPEUTIC TOXICITY | LUN2;31 | SET | 
 
  | 
| 1425 | LNG CHEMOTHERAPY/SURG SEQUENCE | LUN2;32 | SET | 
 
  | 
| 1426 | LNG COMPLICATION #1 | LUN2;33 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1426.1 | LNG COMPLICATION #2 | LUN2;34 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1426.2 | LNG COMPLICATION #3 | LUN2;35 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1426.3 | LNG COMPLICATION #4 | LUN2;36 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1426.4 | LNG COMPLICATION #5 | LUN2;37 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1426.5 | LNG TREATMENT COMPLICATION Y/N | LUN2;40 | SET | ************************REQUIRED FIELD************************ 
 
  | 
| 1427 | LNG CASE ABSTRACTOR INITIALS | LUN2;38 | FREE TEXT | 
  | 
| 1428 | LNG DATE CASE WAS ABSTRACTED | LUN2;39 | DATE | 
  | 
| 1429 | LNG PROXIMAL MARGIN | LUN2;41 | FREE TEXT | 
  | 
| 1429.1 | LNG DISTAL MARGIN | LUN2;42 | FREE TEXT | 
  | 
| 1430 | LNG HCT VAL BEFORE TRANSFUSION | LUN2;43 | NUMBER | 
  | 
| 1500 | GAS PRIOR EXPOSURE TO RAD | GAS1;1 | SET | 
 
  | 
| 1501 | GAS ALCOHOL COMSUMPTION | GAS1;2 | FREE TEXT | 
  | 
| 1502 | GAS MENOPAUSAL STATUS/HOR TX | GAS1;3 | SET | 
 
  | 
| 1503 | GAS H2 BLOCKER/PROTON PUMP | GAS1;4 | SET | 
 
  | 
| 1504 | GAS FAMILY HIST OF GASTRIC CA | GAS1;5 | SET | 
 
  | 
| 1505 | GAS H-PYLORI INFECTION | GAS1;6 | SET | 
 
  | 
| 1506 | GAS DUODENAL ULCER | GAS1;7 | SET | 
 
  | 
| 1507 | GAS GASTRIC ULCER | GAS1;8 | SET | 
 
  | 
| 1508 | GAS HEARTBURN (BENIGN COND) | GAS1;9 | SET | 
 
  | 
| 1509 | GAS PERNICIOUS ANEMIA | GAS1;10 | SET | 
 
  | 
| 1510 | GAS POLYPS OF STOMACH | GAS1;11 | SET | 
 
  | 
| 1511 | GAS POLYPOSIS OF BOWEL | GAS1;12 | SET | 
 
  | 
| 1512 | GAS BARRET'S ESOPHAGUS | GAS1;13 | SET | 
 
  | 
| 1513 | GAS ATROPHIC GASTRITIS | GAS1;14 | SET | 
 
  | 
| 1514 | GAS GASTRIC METAPLASIA | GAS1;15 | SET | 
 
  | 
| 1515 | GAS ANTIBIOTICS | GAS1;16 | SET | 
 
  | 
| 1516 | GAS PROTON PUMP INHIBITORS | GAS1;17 | SET | 
 
  | 
| 1517 | GAS H2 BLOCKERS | GAS1;18 | SET | 
 
  | 
| 1518 | GAS BISMUTH COMPOUNDS | GAS1;19 | SET | 
 
  | 
| 1519 | GAS PRIOR INTRA-ABDOMINAL SURG | GAS1;20 | SET | 
 
  | 
| 1520 | GAS YEAR OF GASTRIC RESECTION | GAS1;21 | FREE TEXT | 
  | 
| 1521 | GAS PERFORMANCE STATUS AT DX | GAS1;22 | SET | 
 
  | 
| 1522 | GAS HEARTBURN (SYMPTOMS) | GAS1;23 | SET | 
 
  | 
| 1523 | GAS FEVER/NIGHT SWEATS | GAS1;24 | SET | 
 
  | 
| 1524 | GAS ACUTE HEMATEMESIS | GAS1;25 | SET | 
 
  | 
| 1525 | GAS TRANSFUSIONS FOR BLD LOSS | GAS1;26 | SET | 
 
  | 
| 1526 | GAS MELENA | GAS1;27 | SET | 
 
  | 
| 1527 | GAS PAIN | GAS1;28 | SET | 
 
  | 
| 1528 | GAS EARLY SATIETY | GAS1;29 | SET | 
 
  | 
| 1529 | GAS CT SCAN OF ABDOMEN | GAS1;30 | SET | 
 
  | 
| 1530 | GAS CT SCAN OF CHEST | GAS1;31 | SET | 
 
  | 
| 1531 | GAS CT PELVIS | GAS1;32 | SET | 
 
  | 
| 1532 | GAS CHEST X-RAY | GAS1;33 | SET | 
 
  | 
| 1533 | GAS GALLIUM SCAN | GAS1;34 | SET | 
 
  | 
| 1534 | GAS BIPEDAL LYMPHANGIOGRAM | GAS1;35 | SET | 
 
  | 
| 1535 | GAS MRI | GAS1;36 | SET | 
 
  | 
| 1536 | GAS PET SCAN | GAS1;37 | SET | 
 
  | 
| 1537 | GAS LAPAROSCOPY | GAS1;38 | SET | 
 
  | 
| 1538 | GAS EUS | GAS1;39 | SET | 
 
  | 
| 1539 | GAS PERITONEAL LAVAGE | GAS1;40 | SET | 
 
  | 
| 1540 | GAS LDH (IU/L) | GAS1;41 | NUMBER | 
  | 
| 1541 | GAS CEA (ng/ml) | GAS1;42 | NUMBER | 
  | 
| 1542 | GAS CA125 (U/ml) | GAS1;43 | NUMBER | 
  | 
| 1543 | GAS BETA2 MICROGLOBULIN | GAS1;44 | NUMBER | 
  | 
| 1544 | GAS URINARY 5-HIAA (mg/24hr) | GAS1;45 | NUMBER | 
  | 
| 1545 | GAS CLINICAL/VISUAL EXAM | GAS1;46 | SET | 
 
  | 
| 1545.1 | GAS BIOPSY | GAS1;47 | SET | 
 
  | 
| 1546 | GAS GASTRO-ESOPHAGEAL JUNCTION | GAS1;48 | SET | 
 
  | 
| 1547 | GAS STOMACH | GAS1;49 | SET | 
 
  | 
| 1547.1 | GAS LIVER | GAS1;50 | SET | 
 
  | 
| 1547.2 | GAS EXTRA-ABDOMINAL | GAS1;51 | SET | 
 
  | 
| 1547.3 | GAS LYMPH NODES | GAS1;52 | SET | 
 
  | 
| 1547.4 | GAS PERITONEUM | GAS1;53 | SET | 
 
  | 
| 1548 | GAS DATE OF FIRST TISSUE DX | GAS1;54 | DATE | 
  | 
| 1549 | GAS LAUREN'S CLASSIFICATION | GAS1;55 | SET | 
 
  | 
| 1550 | GAS GOSEKI'S CLASSIFICATION | GAS1;56 | SET | 
 
  | 
| 1551 | GAS GASTRIN | GAS1;57 | SET | 
 
  | 
| 1551.1 | GAS 5-HIAA | GAS1;58 | SET | 
 
  | 
| 1551.2 | GAS CEA | GAS1;59 | SET | 
 
  | 
| 1551.3 | GAS CA125 | GAS1;60 | SET | 
 
  | 
| 1551.4 | GAS OTHER MOLECULAR MARKER | GAS1;61 | SET | 
 
  | 
| 1552 | GAS MITOTIC RATE | GAS1;62 | SET | 
 
  | 
| 1553 | GAS TUMOR NECROSIS | GAS1;63 | SET | 
 
  | 
| 1554 | GAS FLOW CYTOMETRY/FRESH TISS | GAS1;64 | SET | 
 
  | 
| 1554.1 | GAS IMMUNOHISTOCHEM/FROZEN TIS | GAS1;65 | SET | 
 
  | 
| 1554.2 | GAS IMMUNOHISTOCHEM/PARAFFIN | GAS1;66 | SET | 
 
  | 
| 1554.3 | GAS MOLECULAR GENETICS | GAS1;67 | SET | 
 
  | 
| 1554.4 | GAS POLYMERASE CHAIN REACTION | GAS1;68 | SET | 
 
  | 
| 1554.5 | GAS SOUTHERN BLOT TECHNIQUE | GAS1;69 | SET | 
 
  | 
| 1555 | GAS ANN ARBOR STAGING | GAS1;70 | SET | 
 
  | 
| 1556 | GAS ADHERENCE OF RESECTED PRIM | GAS1;71 | SET | 
 
  | 
| 1557 | GAS MARGIN STAT OF RESECT PRIM | GAS1;72 | SET | 
 
  | 
| 1558 | GAS PROXIMAL MARGIN | GAS1;73 | FREE TEXT | 
  | 
| 1558.1 | GAS DISTAL MARGIN | GAS1;74 | FREE TEXT | 
  | 
| 1559 | GAS SPLEEN | GAS2;1 | SET | 
 
  | 
| 1559.1 | GAS TRANSVERSE COLON | GAS2;2 | SET | 
 
  | 
| 1559.2 | GAS LIVER | GAS2;3 | SET | 
 
  | 
| 1559.3 | GAS DIAPHRAGM | GAS2;4 | SET | 
 
  | 
| 1559.4 | GAS PANCREAS | GAS2;5 | SET | 
 
  | 
| 1559.5 | GAS ABDOMINAL WALL | GAS2;6 | SET | 
 
  | 
| 1559.6 | GAS ADRENAL GLAND | GAS2;7 | SET | 
 
  | 
| 1559.7 | GAS KIDNEY | GAS2;8 | SET | 
 
  | 
| 1559.8 | GAS SMALL INTESTINE | GAS2;9 | SET | 
 
  | 
| 1559.9 | GAS RETROPERITONEUM | GAS2;10 | SET | 
 
  | 
| 1560 | GAS PERIGASTRIC LYMPH NODES | GAS2;11 | SET | 
 
  | 
| 1560.1 | GAS COMMON HEPATIC LYMPH NODES | GAS2;12 | SET | 
 
  | 
| 1560.2 | GAS CELIAC LYMPH NODES | GAS2;13 | SET | 
 
  | 
| 1560.3 | GAS SPLENIC LYMPH NODES | GAS2;14 | SET | 
 
  | 
| 1560.4 | GAS OTHER INTRA-ABDOMINAL NDES | GAS2;15 | SET | 
 
  | 
| 1561 | GAS GROSSLY INVOLVED REG LN | GAS2;16 | SET | 
 
  | 
| 1562 | GAS HCT VAL BEFORE TRANSFUSION | GAS2;17 | NUMBER | 
  | 
| 1563 | GAS TOTAL OPERATIVE BLOOD REPL | GAS2;18 | FREE TEXT | 
  | 
| 1564 | GAS INTRA/PERI-OPERATIVE DEATH | GAS2;19 | SET | 
 
  | 
| 1565 | GAS ANASTOMATIC LEAK | GAS2;20 | SET | 
 
  | 
| 1565.1 | GAS STUMP LEAK | GAS2;21 | SET | 
 
  | 
| 1565.2 | GAS BLEEDING | GAS2;22 | SET | 
 
  | 
| 1565.3 | GAS WOUND INFECTION | GAS2;23 | SET | 
 
  | 
| 1565.4 | GAS SEPSIS | GAS2;24 | SET | 
 
  | 
| 1565.5 | GAS PANCREATITIS | GAS2;25 | SET | 
 
  | 
| 1565.6 | GAS DEAD BOWEL | GAS2;26 | SET | 
 
  | 
| 1565.7 | GAS OTHER COMPLICATIONS | GAS2;27 | SET | 
 
  | 
| 1566 | GAS DATE OF SURGICAL DISCHARGE | GAS2;28 | DATE | 
  | 
| 1567 | GAS INTRA-OPERATIVE RADIATION | GAS2;29 | FREE TEXT | 
  | 
| 1568 | GAS CONCURRENT CHEMOTHERAPY | GAS2;30 | SET | 
 
  | 
| 1569 | GAS INTRAPERITONEAL CMX | GAS2;31 | SET | 
 
  | 
| 1570 | GAS ADMIN OF INTERFERON | GAS2;32 | SET | 
 
  | 
| 1571 | GAS CO-MORBID CONDITION 1 | GAS2;33 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1571.1 | GAS CO-MORBID CONDITION 2 | GAS2;34 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1571.2 | GAS CO-MORBID CONDITION 3 | GAS2;35 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1571.3 | GAS CO-MORBID CONDITION 4 | GAS2;36 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1571.4 | GAS CO-MORBID CONDITION 5 | GAS2;37 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1571.5 | GAS CO-MORBID CONDITION 6 | GAS2;38 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1572 | GAS DURATION OF TOBACCO USE | GAS2;39 | FREE TEXT | 
  | 
| 1573 | GAS PERSONAL HIST OTH MALIG | GAS2;40 | POINTER TO ICDO TOPOGRAPHY FILE (#164) | ICDO TOPOGRAPHY(#164)
  | 
| 1574 | GAS WEIGHT LOSS | GAS2;41 | SET | 
 
  | 
| 1575 | GAS BOOST DOSE (cGy) | GAS2;42 | FREE TEXT | 
  | 
| 1576 | GAS CHEMOTHERAPEUTIC AGENT #1 | GAS2;43 | POINTER TO CHEMOTHERAPEUTIC DRUGS FILE (#164.18) | CHEMOTHERAPEUTIC DRUGS(#164.18)
  | 
| 1576.1 | GAS CHEMOTHERAPEUTIC AGENT #2 | GAS2;44 | POINTER TO CHEMOTHERAPEUTIC DRUGS FILE (#164.18) | CHEMOTHERAPEUTIC DRUGS(#164.18)
  | 
| 1576.2 | GAS CHEMOTHERAPEUTIC AGENT #3 | GAS2;45 | POINTER TO CHEMOTHERAPEUTIC DRUGS FILE (#164.18) | CHEMOTHERAPEUTIC DRUGS(#164.18)
  | 
| 1577 | GAS CHEMOTHERAPEUTIC TOXICITY | GAS2;46 | SET | 
 
  | 
| 1578 | GAS CHEMOTHERAPY/SURG SEQUENCE | GAS2;47 | SET | 
 
  | 
| 1579 | GAS COMPLICATION #1 | GAS2;48 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1579.1 | GAS COMPLICATION #2 | GAS2;49 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1579.2 | GAS COMPLICATION #3 | GAS2;50 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1579.3 | GAS COMPLICATION #4 | GAS2;51 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1579.4 | GAS COMPLICATION #5 | GAS2;52 | POINTER TO ICD DIAGNOSIS FILE (#80) | ICD DIAGNOSIS(#80)
  | 
| 1764 | SUMMARY STAGE 2018 | EOD;4 | SET | 
 
  | 
| 1772 | EOD PRIMARY TUMOR | EOD;1 | NUMBER | 
  | 
| 1774 | EOD REGIONAL NODES | EOD;2 | NUMBER | 
  | 
| 1776 | EOD METS | EOD;3 | NUMBER | 
  | 
| 2000 | DIVISION | DIV;1 | POINTER TO INSTITUTION FILE (#4) | ************************REQUIRED FIELD************************ INSTITUTION(#4)
  | 
| 3000 | CLASS OF CASE CONVERSION FLAG | CONV;1 | SET | 
 
  | 
| 3001 | STATE AT DX CONVERSION FLAG | CONV;2 | SET | 
 
  | 
| 3700 | SEER SSF1-HPV STATUS | SSD4;33 | POINTER TO ONCO HPV STATUS FILE (#167.7) | ONCO HPV STATUS(#167.7)
  | 
| 3800 | SCHEMA ID | SSD1;1 | FREE TEXT | 
  | 
| 3800.1 | SCHEMA ID DESCRIPTION | SSD5;6 | FREE TEXT | 
  | 
| 3801 | CHROMOSOME 1P: (LOH) | SSD1;2 | SET | 
 
  | 
| 3802 | CHROMOSOME 19Q: (LOH) | SSD1;3 | SET | 
 
  | 
| 3803 | ADENOID CYSTIC BASALOID PTTRN | SSD1;4 | FREE TEXT | 
  | 
| 3804 | ADENOPATHY | SSD1;5 | SET | 
 
  | 
| 3805 | AFP POST-ORCHIECTOMY LAB VAL | SSD1;6 | FREE TEXT | 
  | 
| 3806 | AFP POST-ORCHIECTOMY RANGE | SSD1;7 | SET | 
 
  | 
| 3807 | AFP PRE-ORCHIECTOMY LAB VALUE | SSD1;8 | FREE TEXT | 
  | 
| 3808 | AFP PRE-ORCHIECTOMY RANGE | SSD1;9 | SET | 
 
  | 
| 3809 | AFP PRETREATMENT INTERPRET | SSD1;10 | SET | 
 
  | 
| 3810 | AFP PRETREATMENT LAB VALUE | SSD1;11 | FREE TEXT | 
  | 
| 3811 | ANEMIA | SSD1;12 | SET | 
 
  | 
| 3812 | B SYMPTOMS | SSD1;13 | SET | 
 
  | 
| 3813 | BILIRUBIN PRE TOTAL LAB VALUE | SSD1;14 | FREE TEXT | 
  | 
| 3814 | BILIRUBIN PRETREATMENT UNIT | SSD1;15 | SET | 
 
  | 
| 3815 | BONE INVASION | SSD1;16 | SET | 
 
  | 
| 3816 | BRAIN MOLECULAR MARKERS | SSD1;17 | POINTER TO ONCO BRAIN MOLECULAR MARKERS FILE (#167.1) | ONCO BRAIN MOLECULAR MARKERS(#167.1)
  | 
| 3817 | BRESLOW TUMOR THICKNESS | SSD1;18 | FREE TEXT | 
  | 
| 3818 | CA-125 PRETREATMENT INTER | SSD1;19 | SET | 
 
  | 
| 3819 | CEA PRETREATMENT INTER | SSD1;20 | SET | 
 
  | 
| 3820 | CEA PRETREATMENT LAB VALUE | SSD1;21 | FREE TEXT | 
  | 
| 3821 | CHROMOSOME 3 STATUS | SSD1;22 | SET | 
 
  | 
| 3822 | CHROMOSOME 8Q STATUS | SSD1;23 | SET | 
 
  | 
| 3823 | CIRCUMFERENTIAL RESECT MARGIN | SSD1;24 | FREE TEXT | 
  | 
| 3824 | CREATININE PRETREAT LAB VALUE | SSD1;25 | FREE TEXT | 
  | 
| 3825 | CREATININE PRETREAT UNIT | SSD1;26 | SET | 
 
  | 
| 3826 | ER PERCENT POSITIVE | SSD1;27 | FREE TEXT | 
  | 
| 3827 | ER SUMMARY | SSD1;28 | SET | 
 
  | 
| 3828 | ER ALLRED SCORE | SSD1;29 | FREE TEXT | 
  | 
| 3829 | ESOPHAGUS EGJ TUMOR EPICENTER | SSD1;30 | SET | 
 
  | 
| 3830 | ENE CLIN (NON-HEAD AND NECK) | SSD1;31 | SET | 
 
  | 
| 3831 | ENE HEAD AND NECK CLINICAL | SSD1;32 | SET | 
 
  | 
| 3832 | ENE HEAD AND NECK PATHOLOGICAL | SSD1;33 | FREE TEXT | 
  | 
| 3833 | ENE PATH (NON-HEAD AND NECK) | SSD1;34 | SET | 
 
  | 
| 3834 | EXTRAVASCULAR MATRIX PATTERNS | SSD1;35 | SET | 
 
  | 
| 3835 | FIBROSIS SCORE | SSD2;1 | SET | 
 
  | 
| 3836 | FIGO STAGE | SSD2;2 | FREE TEXT | 
  | 
| 3837 | GESTATIONAL TROPHOBLASTIC | SSD2;3 | FREE TEXT | 
  | 
| 3838 | GLEASON PATTERNS CLINICAL | SSD2;4 | POINTER TO GLEASON PATTERNS FILE (#167.2) | GLEASON PATTERNS(#167.2)
  | 
| 3839 | GLEASON PATTERNS PATHOLOGICAL | SSD2;5 | POINTER TO GLEASON PATTERNS FILE (#167.2) | GLEASON PATTERNS(#167.2)
  | 
| 3840 | GLEASON SCORE CLINICAL | SSD2;6 | SET | 
 
  | 
| 3841 | GLEASON SCORE PATHOLOGICAL | SSD2;7 | SET | 
 
  | 
| 3842 | GLEASON TERTIARY PATTERN | SSD2;8 | SET | 
 
  | 
| 3846 | HCG POST-ORCHIECTOMY LAB VALUE | SSD2;12 | FREE TEXT | 
  | 
| 3847 | HCG POST-ORCHIECTOMY RANGE | SSD2;13 | SET | 
 
  | 
| 3848 | HCG PRE-ORCHIECTOMY LAB VALUE | SSD2;14 | FREE TEXT | 
  | 
| 3849 | HCG PRE-ORCHIECTOMY RANGE | SSD2;15 | SET | 
 
  | 
| 3850 | HER2 IHC SUMMARY | SSD2;16 | SET | 
 
  | 
| 3851 | HER2 ISH DUAL PROBE COPY NUM | SSD2;17 | FREE TEXT | 
  | 
| 3852 | HER2 ISH DUAL PROBE RATIO | SSD2;18 | FREE TEXT | 
  | 
| 3853 | HER2 ISH SINGLE PROBE COPY NUM | SSD2;19 | FREE TEXT | 
  | 
| 3854 | HER2 ISH SUMMARY | SSD2;20 | SET | 
 
  | 
| 3855 | HER2 OVERALL SUMMARY | SSD2;21 | SET | 
 
  | 
| 3856 | HERITABLE TRAIT | SSD2;22 | SET | 
 
  | 
| 3857 | HIGH RISK CYTOGENETICS | SSD2;23 | SET | 
 
  | 
| 3858 | HIGH RISK HISTOLOGIC FEATURES | SSD2;24 | SET | 
 
  | 
| 3859 | HIV STATUS | SSD2;25 | SET | 
 
  | 
| 3860 | INR PROTHROMBIN TIME | SSD2;26 | FREE TEXT | 
  | 
| 3861 | IPSILATERANL ADRENAL GLAND INV | SSD2;27 | SET | 
 
  | 
| 3862 | JAK2 | SSD2;28 | SET | 
 
  | 
| 3863 | KI-67 | SSD2;29 | FREE TEXT | 
  | 
| 3864 | INVASION BEYOND CAPSULE | SSD2;30 | SET | 
 
  | 
| 3865 | KIT GENE IMMUNOHISTOCHEMISTRY | SSD2;31 | SET | 
 
  | 
| 3866 | KRAS | SSD2;32 | SET | 
 
  | 
| 3867 | LDH POST-ORCHIECTOMY RANGE | SSD2;33 | SET | 
 
  | 
| 3868 | LDH PRE-ORCHIECTOMY RANGE | SSD2;34 | SET | 
 
  | 
| 3869 | LDH LEVEL | SSD2;35 | SET | 
 
  | 
| 3870 | LDH UPPER LIMITS OF NORMAL | SSD2;36 | FREE TEXT | 
  | 
| 3871 | LN ASSESS METH FEMORAL-INGUIN | SSD3;1 | SET | 
 
  | 
| 3872 | LN ASSESS METHOD PARA-AORTIC | SSD3;2 | SET | 
 
  | 
| 3873 | LN ASSESSMENT METHOD PELVIC | SSD3;3 | SET | 
 
  | 
| 3874 | LN DISTANT ASSESSMENT METHOD | SSD3;4 | SET | 
 
  | 
| 3875 | LN DISTANT MEDIASTINAL,SCALENE | SSD3;5 | SET | 
 
  | 
| 3876 | LN HEAD & NECK LEVELS I-III | SSD3;6 | SET | 
 
  | 
| 3877 | LN HEAD & NECK LEVELS IV-V | SSD3;7 | SET | 
 
  | 
| 3878 | LN HEAD & NECK LEVELS VI-VII | SSD3;8 | SET | 
 
  | 
| 3879 | LN HEAD AND NECK OTHER | SSD3;9 | SET | 
 
  | 
| 3880 | LN ISOLATED TUMOR CELLS (ITC) | SSD3;10 | SET | 
 
  | 
| 3881 | LN LATERALITY | SSD3;11 | SET | 
 
  | 
| 3882 | LN POSITIVE AXILLARY LVL I-II | SSD3;12 | FREE TEXT | 
  | 
| 3883 | LN SIZE | SSD3;13 | FREE TEXT | 
  | 
| 3884 | LN STATUS FEM-ING,PAR-AOR,PLV | SSD3;14 | POINTER TO ONCO LN STATUS FILE (#167.3) | ONCO LN STATUS(#167.3)
  | 
| 3885 | LYMPHOCYTOSIS | SSD3;15 | SET | 
 
  | 
| 3886 | MAJOR VEIN INVOLVEMENT | SSD3;16 | SET | 
 
  | 
| 3887 | MEASURED BASAL DIAMETER | SSD3;17 | FREE TEXT | 
  | 
| 3888 | MEASURED THICKNESS | SSD3;18 | FREE TEXT | 
  | 
| 3889 | METHYLATION OF MGMT | SSD3;19 | SET | 
 
  | 
| 3890 | MICROSATELLITE INSTABILITY | SSD3;20 | SET | 
 
  | 
| 3891 | MICROVASCULAR DENSITY | SSD3;21 | FREE TEXT | 
  | 
| 3892 | MITOTIC COUNT UVEAL MELANOMA | SSD3;22 | FREE TEXT | 
  | 
| 3893 | MITOTIC RATE MELANOMA | SSD3;23 | FREE TEXT | 
  | 
| 3894 | MULTIGENE SIGNATURE METHOD | SSD3;24 | SET | 
 
  | 
| 3895 | MULTIGENE SIGNATURE RESULTS | SSD3;25 | FREE TEXT | 
  | 
| 3896 | NCCN IPI | SSD3;26 | FREE TEXT | 
  | 
| 3897 | NUMBER OF CORES EXAMINED | SSD3;27 | FREE TEXT | 
  | 
| 3898 | NUMBER OF CORES POSITIVE | SSD3;28 | FREE TEXT | 
  | 
| 3899 | NUM OF EXAMINED PARA-AORTIC | SSD3;29 | FREE TEXT | 
  | 
| 3900 | NUM OF EXAMINED PELVIC NODES | SSD3;30 | FREE TEXT | 
  | 
| 3901 | NUM OF POS PARA-AORTIC NODES | SSD3;31 | FREE TEXT | 
  | 
| 3902 | NUM OF POSITIVE PELVIC NODES | SSD3;32 | FREE TEXT | 
  | 
| 3903 | ONCOTYPE DX RECUR SCORE-DCIS | SSD3;33 | FREE TEXT | 
  | 
| 3904 | ONCOTYPE DX REC SCORE-INVASIVE | SSD3;34 | FREE TEXT | 
  | 
| 3905 | ONCOTYPE DX RISK LEVEL-DCIS | SSD4;1 | SET | 
 
  | 
| 3906 | ONCOTYPE DX RISK LEVEL-INVAS | SSD4;2 | SET | 
 
  | 
| 3907 | ORGANOMEGALY | SSD4;3 | SET | 
 
  | 
| 3908 | PERCENT NECROSIS PST NEOADJVNT | SSD4;4 | FREE TEXT | 
  | 
| 3909 | PERINEURAL INVASION 2018 | SSD4;5 | SET | 
 
  | 
| 3910 | PERIPHERAL BLOOD INVOLV 2018 | SSD4;6 | POINTER TO ONCO PERIPHERAL BLOOD INVOLVEMENT FILE (#167.4) | ONCO PERIPHERAL BLOOD INVOLVEMENT(#167.4)
  | 
| 3911 | PERITONEAL CYTOLOGY | SSD4;7 | SET | 
 
  | 
| 3913 | PLEURAL EFFUSION | SSD4;8 | SET | 
 
  | 
| 3914 | PR PERCENT POSITIVE | SSD4;9 | FREE TEXT | 
  | 
| 3915 | PR SUMMARY | SSD4;10 | SET | 
 
  | 
| 3916 | PR ALLRED SCORE | SSD4;11 | FREE TEXT | 
  | 
| 3917 | PRIMARY SCLEROSING CHOLANGITIS | SSD4;12 | SET | 
 
  | 
| 3918 | PROFOUND IMMUNE SUPPRESSION | SSD4;13 | SET | 
 
  | 
| 3919 | PROSTATE PATHOLOGICAL EXT | SSD4;14 | FREE TEXT | 
  | 
| 3920 | PSA LAB VALUE | SSD4;15 | FREE TEXT | 
  | 
| 3921 | RESIDUAL TUM VOL PST CYTO | SSD4;16 | POINTER TO ONCO RESIDUAL TUMOR VOLUME FILE (#167.5) | ONCO RESIDUAL TUMOR VOLUME(#167.5)
  | 
| 3922 | RESPONSE TO NEOADJUVANT THERA | SSD4;17 | SET | 
 
  | 
| 3923 | S CATEGORY CLINICAL | SSD4;18 | SET | 
 
  | 
| 3924 | S CATEGORY PATHOLOGICAL | SSD4;19 | SET | 
 
  | 
| 3925 | SARCOMATOID FEATURES | SSD4;20 | FREE TEXT | 
  | 
| 3926 | SCHEMA DISCRIMINATOR 1 | SSD4;21 | NUMBER | 
  | 
| 3927 | SCHEMA DISCRIMINATOR 2 | SSD4;22 | NUMBER | 
  | 
| 3928 | SCHEMA DISCRIMINATOR 3 | SSD4;23 | NUMBER | 
  | 
| 3929 | SEPARATE TUMOR NODULES | SSD4;24 | SET | 
 
  | 
| 3930 | SERUM ALBUMIN PRETREAT VALUE | SSD4;25 | SET | 
 
  | 
| 3931 | SERUM BETA-2 MICROGLOBULIN | SSD4;26 | SET | 
 
  | 
| 3932 | LDH LAB VALUE | SSD4;27 | FREE TEXT | 
  | 
| 3933 | THROMBOCYTOPENIA | SSD4;28 | SET | 
 
  | 
| 3934 | TUMOR DEPOSITS | SSD4;29 | FREE TEXT | 
  | 
| 3935 | TUMOR GROWTH PATTERN | SSD4;30 | SET | 
 
  | 
| 3936 | ULCERATION 2018 | SSD4;31 | SET | 
 
  | 
| 3937 | VISCERAL PARIETAL PLEURAL INV | SSD4;32 | SET | 
 
  | 
| 3938 | ALK REARRANGEMENT | SSD5;1 | SET | 
 
  | 
| 3939 | EGFR MUTATIONAL ANALYSIS | SSD5;2 | SET | 
 
  | 
| 3940 | BRAF MUTATIONAL ANALYSIS | SSD5;3 | SET | 
 
  | 
| 3941 | NRAS MUTATIONAL ANALYSIS | SSD5;4 | SET | 
 
  | 
| 3942 | CA 19-9 PRETX LAB VALUE | SSD5;5 | FREE TEXT | 
  | 
| 3943 | NCDB-SARSCOV2-TEST | NCR21;1 | SET | 
 
  | 
| 3944 | NCDB-SARSCOV2-POSITIVE | NCR21;2 | SET | 
 
  | 
| 3945 | NCDB-SARSCOV2-POSITIVE DATE | NCR21;3 | DATE | 
  | 
| 3946 | NCDB-COVID19-TX IMPACT | NCR21;4 | SET | 
 
  | 
| 3950 | MACROSCOPIC EVAL OF MESORECTUM | SSD5;7 | SET | 
 
  | 
| 3955 | DERIVED RAI STAGE | SSD5;8 | SET | 
 
  | 
| 3956 | P16 | SSD5;9 | SET | 
 
  | 
| 3957 | LN STATUS PELVIC | SSD5;10 | SET | 
 
  | 
| 3958 | LN STATUS PARA-AORTIC | SSD5;11 | SET | 
 
  | 
| 3959 | LN STATUS FEMORAL-INGUINAL | SSD5;12 | SET | 
 
  | 
| 3960 | HISTOLOGIC SUBTYPE | SSD5;13 | SET | 
 
  | 
| 3961 | CLINICAL MARGIN WIDTH | SSD5;14 | FREE TEXT | 
  | 
| 3964 | BRAIN PRIMARY TUMOR LOCATION | SSD5;17 | SET | 
 
  | 
| 5000 | AJCC ID | AJCC8;1 | FREE TEXT | 
  | 
| 5001 | AJCC TNM CLIN T | AJCC8;2 | FREE TEXT | 
  | 
| 5002 | AJCC TNM CLIN N | AJCC8;3 | FREE TEXT | 
  | 
| 5003 | AJCC TNM CLIN M | AJCC8;4 | FREE TEXT | 
  | 
| 5004 | AJCC TNM CLIN STAGE GROUP | AJCC8;5 | FREE TEXT | 
  | 
| 5011 | AJCC TNM PATH T | AJCC8;6 | FREE TEXT | 
  | 
| 5012 | AJCC TNM PATH N | AJCC8;7 | FREE TEXT | 
  | 
| 5013 | AJCC TNM PATH M | AJCC8;8 | FREE TEXT | 
  | 
| 5014 | AJCC TNM PATH STAGE GROUP | AJCC8;9 | FREE TEXT | 
  | 
| 5021 | AJCC TNM POST THER (yp) T | AJCC8;10 | FREE TEXT | 
  | 
| 5022 | AJCC TNM POST THER (yp) N | AJCC8;11 | FREE TEXT | 
  | 
| 5023 | AJCC TNM POST THER (yp) M | AJCC8;12 | FREE TEXT | 
  | 
| 5024 | AJCC TNM POST THER (yp) SG | AJCC8;13 | FREE TEXT | 
  | 
| 5025 | AJCC TNM POST THER (yc) T | AJCC8;20 | FREE TEXT | 
  | 
| 5026 | AJCC TNM POST THER (yc) N | AJCC8;21 | FREE TEXT | 
  | 
| 5027 | AJCC TNM POST THER (yc) M | AJCC8;22 | FREE TEXT | 
  | 
| 5028 | AJCC TNM POST THER (yc) SG | AJCC8;23 | FREE TEXT | 
  | 
| 5031 | AJCC TNM CLIN T SUFFIX | AJCC8;14 | FREE TEXT | 
  | 
| 5032 | AJCC TNM PATH T SUFFIX | AJCC8;16 | FREE TEXT | 
  | 
| 5033 | AJCC TNM POST THER (yp) T SFX | AJCC8;18 | FREE TEXT | 
  | 
| 5033.5 | AJCC TNM POST THER (yc) T SFX | AJCC8;24 | FREE TEXT | 
  | 
| 5034 | AJCC TNM CLIN N SUFFIX | AJCC8;15 | FREE TEXT | 
  | 
| 5035 | AJCC TNM PATH N SUFFIX | AJCC8;17 | FREE TEXT | 
  | 
| 5036 | AJCC TNM POST THER (yp) N SFX | AJCC8;19 | FREE TEXT | 
  | 
| 5036.5 | AJCC TNM POST THER (yc) N SFX | AJCC8;25 | FREE TEXT | 
  | 
| 5501 | PHASE 1 DOSE PER FRACTION | RAD18;1 | FREE TEXT | 
  | 
| 5502 | PHASE 1 RAD EXT BEAM PLAN TECH | RAD18;2 | POINTER TO ONCO RADIATION EXTERNAL BEAM FILE (#164.81) | ONCO RADIATION EXTERNAL BEAM(#164.81)
  | 
| 5503 | PHASE 1 NUMBER OF FRACTIONS | RAD18;3 | FREE TEXT | 
  | 
| 5504 | PHASE 1 RAD TREATMENT VOLUME | RAD18;4 | POINTER TO ONCO RADIATION TREATMENT VOLUME FILE (#164.82) | ONCO RADIATION TREATMENT VOLUME(#164.82)
  | 
| 5505 | PHASE 1 RAD TO DRAINING LN | RAD18;5 | POINTER TO ONCO RADIATION TO DRAINING LN FILE (#164.83) | ONCO RADIATION TO DRAINING LN(#164.83)
  | 
| 5506 | PHASE 1 RAD TREATMENT MODALITY | RAD18;6 | POINTER TO ONCO RADIATION TREATMENT MODALITY FILE (#164.84) | ONCO RADIATION TREATMENT MODALITY(#164.84)
  | 
| 5507 | PHASE 1 TOTAL DOSE | RAD18;7 | FREE TEXT | 
  | 
| 5511 | PHASE 2 DOSE PER FRACTION | RAD18;8 | FREE TEXT | 
  | 
| 5512 | PHASE 2 RAD EXT BEAM PLAN TECH | RAD18;9 | POINTER TO ONCO RADIATION EXTERNAL BEAM FILE (#164.81) | ONCO RADIATION EXTERNAL BEAM(#164.81)
  | 
| 5513 | PHASE 2 NUMBER OF FRACTIONS | RAD18;10 | FREE TEXT | 
  | 
| 5514 | PHASE 2 RAD TREATMENT VOLUME | RAD18;11 | POINTER TO ONCO RADIATION TREATMENT VOLUME FILE (#164.82) | ONCO RADIATION TREATMENT VOLUME(#164.82)
  | 
| 5515 | PHASE 2 RAD TO DRAINING LN | RAD18;12 | POINTER TO ONCO RADIATION TO DRAINING LN FILE (#164.83) | ONCO RADIATION TO DRAINING LN(#164.83)
  | 
| 5516 | PHASE 2 RAD TREATMENT MODALITY | RAD18;13 | POINTER TO ONCO RADIATION TREATMENT MODALITY FILE (#164.84) | ONCO RADIATION TREATMENT MODALITY(#164.84)
  | 
| 5517 | PHASE 2 TOTAL DOSE | RAD18;14 | FREE TEXT | 
  | 
| 5521 | PHASE 3 DOSE PER FRACTION | RAD18;15 | FREE TEXT | 
  | 
| 5522 | PHASE 3 RAD EXT BEAM PLAN TECH | RAD18;16 | POINTER TO ONCO RADIATION EXTERNAL BEAM FILE (#164.81) | ONCO RADIATION EXTERNAL BEAM(#164.81)
  | 
| 5523 | PHASE 3 NUMBER OF FRACTIONS | RAD18;17 | FREE TEXT | 
  | 
| 5524 | PHASE 3 RAD TREATMENT VOLUME | RAD18;18 | POINTER TO ONCO RADIATION TREATMENT VOLUME FILE (#164.82) | ONCO RADIATION TREATMENT VOLUME(#164.82)
  | 
| 5525 | PHASE 3 RAD TO DRAINING LN | RAD18;19 | POINTER TO ONCO RADIATION TO DRAINING LN FILE (#164.83) | ONCO RADIATION TO DRAINING LN(#164.83)
  | 
| 5526 | PHASE 3 RAD TREATMENT MODALITY | RAD18;20 | POINTER TO ONCO RADIATION TREATMENT MODALITY FILE (#164.84) | ONCO RADIATION TREATMENT MODALITY(#164.84)
  | 
| 5527 | PHASE 3 TOTAL DOSE | RAD18;21 | FREE TEXT | 
  | 
| 7000 | STATE AT DX GEOCODE 1970/80/90 | NCR18;1 | POINTER TO STATE FILE (#5) | STATE(#5)
  | 
| 7001 | STATE AT DX GEOCODE 2010 | NCR18;2 | POINTER TO STATE FILE (#5) | STATE(#5)
  | 
| 7002 | BEHAVIOR (73-91) ICD-O-1 | NCR18;3 | NUMBER | 
  | 
| 7003 | GRADE (73-91) ICD-O-1 | NCR18;4 | NUMBER | 
  | 
| 7004 | RUCA 2000 | NCR18;5 | SET | 
 
  | 
| 7005 | RUCA 2010 | NCR18;6 | SET | 
 
  | 
| 7006 | URIC 2000 | NCR18;7 | SET | 
 
  | 
| 7007 | URIC 2010 | NCR18;8 | SET | 
 
  | 
| 7008 | DERIVED EOD 2018 T | NCR18;9 | FREE TEXT | 
  | 
| 7009 | DERIVED EOD 2018 N | NCR18;10 | FREE TEXT | 
  | 
| 7010 | DERIVED EOD 2018 M | NCR18;11 | FREE TEXT | 
  | 
| 7011 | DERIVED EOD 2018 STAGE GROUP | NCR18;12 | FREE TEXT | 
  | 
| 7012 | DERIVED SUMMARY STAGE 2018 | NCR18;13 | SET | 
 
  | 
| 7013 | DATE REGIONAL LN DISSECTION | NCR18;14 | DATE | 
  | 
| 7014 | DATE REG LN DISSECTION FLAG | NCR18;15 | SET | 
 
  | 
| 7015 | SENTINEL LYMPH NODES POSITIVE | NCR18;16 | FREE TEXT | 
  | 
| 7016 | SENTINEL LYMPH NODES EXAMINED | NCR18;17 | FREE TEXT | 
  | 
| 7017 | DATE OF SENTINEL LN BIOPSY | NCR18;18 | DATE | 
  | 
| 7018 | DATE OF SENTINEL LN BIOPSY FLG | NCR18;19 | SET | 
 
  | 
| 7019 | NPCR DERIVED AJCC8 CLN STG GRP | NCR18;20 | FREE TEXT | 
  | 
| 7020 | NPCR DERIVED AJCC8 PTH STG GRP | NCR18;21 | FREE TEXT | 
  | 
| 7021 | NPCR DERIVED AJCC8 PT STG GRP | NCR18;22 | FREE TEXT | 
  | 
| 7022 | NPCR SPECIFIC FIELD | NCR18;23 | FREE TEXT | 
  | 
| 7023 | STATE AT DX GEOCODE 2000 | NCR18;24 | POINTER TO STATE FILE (#5) | STATE(#5)
  | 
| 7024 | NUMBER OF PHASES RAD TX | NCR18B;1 | SET | 
 
  | 
| 7025 | RADIATION TREATMENT DISC EARLY | NCR18B;2 | SET | 
 
  | 
| 7026 | TOTAL DOSE | NCR18B;3 | FREE TEXT | 
  | 
| 7027 | OVER-RIDE TNM STAGE | NCR18B;4 | SET | 
 
  | 
| 7028 | OVER-RIDE TNM TIS | NCR18B;5 | SET | 
 
  | 
| 7029 | OVER-RIDE TNM 3 | NCR18B;6 | SET | 
 
  | 
| 7030 | OVER-RIDE NAME/SEX | NCR18B;7 | SET | 
 
  | 
| 7031 | HISTOLOGY (73-91) ICD-O-1 | NCR18B;8 | NUMBER | 
  | 
| 7032 | RQRS NCDB SUBMISSION FLAG | NCR18B;9 | SET | 
 
  | 
| 7033 | COC ACCREDITED FLAG | NCR18B;10 | SET | 
 
  | 
| 7034 | VITAL STATUS RECODE | NCR18B;11 | SET | 
 
  | 
| 7037 | RECORD NUMBER RECODE | NCR18B;14 | NUMBER | 
  | 
| 7038 | SEER CAUSE SPECIFIC COD | NCR18B;15 | SET | 
 
  | 
| 7039 | SEER OTHER COD | NCR18B;16 | SET | 
 
  | 
| 7040 | MEDICARE BENEFICIARY ID | NCR18B;17 | FREE TEXT | 
  | 
| 10104 | RX HOSP--SURG BREAST | 3.2;4 | FREE TEXT | 
  | 
| 10105 | RX SUMM--SURG BREAST | 3.2;5 | FREE TEXT | 
  | 
| 10106 | RX HOSP--RECON BREAST 22-23 | 3.2;6 | FREE TEXT | 
  | 
| 10107 | RX SUMM--RECON BREAST 22-23 | 3.2;7 | FREE TEXT | 
  | 
| 10108 | RX HOSP--RECON BREAST | 3.2;10 | FREE TEXT | 
  | 
| 10109 | RX SUMM--RECON BREAST | 3.2;11 | FREE TEXT | 
  | 
| ICR LINK | Subscribing Package(s) | Fields Referenced | Description | 
|---|---|---|---|
| ICR #2888 | DATE DX (3).  Access: Read w/Fileman ICDO-TOPOGRAPHY (20). Access: Read w/Fileman HISTOLOGY (22). Access: Read w/Fileman GRADE/DIFFERENTIATION (24). Access: Read w/Fileman SIZE OF TUMOR (29). Access: Read w/Fileman CLINICAL STAGE GROUP (38). Access: Read w/Fileman CLINICAL T (37.1). Access: Read w/Fileman CLINICAL N (37.2). Access: Read w/Fileman CLINICAL M (37.3). Access: Read w/Fileman PATHOLOGIC T (85). Access: Read w/Fileman PATHOLOGIC N (86). Access: Read w/Fileman PATHOLOGIC M (87). Access: Read w/Fileman PATHOLOGIC STAGE GROUP (88). Access: Read w/Fileman SURGERY OF PRIMARY SITE DATE (50). Access: Read w/Fileman RADIATION DATE (51). Access: Read w/Fileman RADIATION (51.2). Access: Read w/Fileman CHEMOTHERAPY DATE (53). Access: Read w/Fileman CHEMOTHERAPY (53.2). Access: Read w/Fileman HORMONE THERAPY DATE (54). Access: Read w/Fileman HORMONE THERAPY (54.2). Access: Read w/Fileman IMMUNOTHERAPY DATE (55). Access: Read w/Fileman IMMUNOTHERAPY (BRM) (55.2). Access: Read w/Fileman RADIATION TREATMENT VOLUME (125). Access: Read w/Fileman NON CANCER-DIRECTED SURGERY (58.1). Access: Read w/Fileman INTENT OF RADIATION (127). Access: Read w/Fileman NON CANCER-DIRECTED SURG DATE (58.3). Access: Read w/Fileman SURGERY OF PRIMARY SITE (58.2). Access: Read w/Fileman RADIATION COMPLETION STATUS (128). Access: Read w/Fileman ABSTRACT STATUS (91). Access: Read w/Fileman PROTOCOL ELIGIBILITY STATUS (346). Access: Read w/Fileman PROTOCOL PARTICIPATION (560). Access: Read w/Fileman REGIONAL DOSE:cGy (442). Access: Read w/Fileman  |